Archive for the ‘BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics’ Category

re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. 

Posted in Advanced Computing Platform, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Blockchain Transactions System, Machine Learning, Natural Language Processing (NLP) on November 18, 2020| Leave a Comment »

re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. 

 

Preview the tracks that will be available, along with the general agenda, on the website. 

 

https://reinvent.awsevents.com/

 

https://virtual.awsevents.com/agenda

 

awsreinvent-support@amazon.com

AWS re:Invent 2020 – Life Sciences Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. Hear how AWS experts and inspiring members of the Life Sciences & Genomics industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Life Sciences attendees looking to get the most out of their experience, follow these steps:

• Register for re:Invent.
• Take a look at all of the Life Sciences sessions available, as well as lots of other information and additional activities, in our curated Life Sciences Attendee Guide coming soon!
• Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Life Sciences at re:Invent 2020

AWS enables pharma and biotech companies to transform every stage of the pharma value chain, with services that enhance data liquidity, operational excellence, and customer engagement. AWS is the trusted technology provider with the cost-effective compute and storage, machine learning capabilities, and customer-centric know how to help companies embrace innovation and bring differentiated therapeutics to market faster.

Dates and Presentation Title

BlockChain Architecture

DEC 1, 2020 | 12:00 AM – 12:20 AM EST

Nestlé brings supply chain transparency with Amazon Managed Blockchain

Chain of origin is the Nestlé answer to complete supply chain transparency, from crop to coffee cup, with technology at its heart. Today, consumers want to know about the quality of their product and know where it is sourced from. Using AWS and Amazon Man

… Learn More

Add To Calendar

Blockchain Retail

Thursday, December 10

DEC 10, 2020 | 3:15 PM – 3:45 PM EST

Trust and transparency in live virtual events

This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.

Add To Calendar

Architecture Blockchain

DEC 10, 2020 | 11:15 PM – 11:45 PM EST

Trust and transparency in live virtual events

This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.

Add To Calendar

Architecture Blockchain

Friday, December 11

DEC 11, 2020 | 7:15 AM – 7:45 AM EST

Trust and transparency in live virtual events

This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.

Add To Calendar

Architecture Blockchain

Tuesday, December 15

DEC 15, 2020 | 4:00 PM – 4:30 PM EST

What’s new in Amazon Managed Blockchain

Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar

Blockchain Financial Services

Wednesday, December 16

DEC 16, 2020 | 12:00 AM – 12:30 AM EST

What’s new in Amazon Managed Blockchain

Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar

Blockchain Financial Services

DEC 16, 2020 | 8:00 AM – 8:30 AM EST

What’s new in Amazon Managed Blockchain

Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar

Blockchain Financial Services

Life Science and Healthcare

DEC 1, 2020 | 12:00 AM – 12:20 AM EST

Building robots to help hospitals become safer and smarter

In hospitals and other healthcare venues, robots increasingly perform contactless delivery and autonomous maintenance services to reduce the risk of exposing patients and medical staff to harmful viruses and bacteria. In this session, see how Solaris JetBrain and M

… Learn More

Add To Calendar

Robotics IoT

DEC 1, 2020 | 5:15 PM – 5:45 PM EST

Transform research environments with Service Workbench on AWS

Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.

Add To Calendar

Public Sector Healthcare

Wednesday, December 2

DEC 2, 2020 | 1:15 AM – 1:45 AM EST

Transform research environments with Service Workbench on AWS

Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.

Add To Calendar

Public Sector Healthcare

DEC 2, 2020 | 9:15 AM – 9:45 AM EST

Transform research environments with Service Workbench on AWS

Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.

Add To Calendar

Public Sector Healthcare

DEC 2, 2020 | 11:00 AM – 11:30 AM EST

Reinventing medical imaging with machine learning on AWS

It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 2, 2020 | 2:45 PM – 3:15 PM EST

Making healthcare more personal with MetroPlus Health

COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar

Healthcare Public Sector

DEC 2, 2020 | 4:15 PM – 4:45 PM EST

Securing protected health information and high-risk datasets

Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar

Healthcare Life Sciences

DEC 2, 2020 | 5:45 PM – 6:15 PM EST

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 

In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More

Add To Calendar

Public Sector Partner Solutions for Business

DEC 2, 2020 | 6:30 PM – 7:00 PM EST

How Vyaire uses AWS analytics to scale ventilator production & save lives

When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar

Analytics Healthcare

DEC 2, 2020 | 7:00 PM – 7:30 PM EST

Reinventing medical imaging with machine learning on AWS

It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 2, 2020 | 10:45 PM – 11:15 PM EST

Making healthcare more personal with MetroPlus Health

COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar

Healthcare Public Sector

Thursday, December 3

DEC 3, 2020 | 12:15 AM – 12:45 AM EST

Securing protected health information and high-risk datasets

Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar

Healthcare Life Sciences

DEC 3, 2020 | 1:45 AM – 2:15 AM EST

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 

In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More

Add To Calendar

Public Sector Partner Solutions for Business

DEC 3, 2020 | 2:30 AM – 3:00 AM EST

How Vyaire uses AWS analytics to scale ventilator production & save lives

When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar

Analytics Healthcare

DEC 3, 2020 | 3:00 AM – 3:30 AM EST

Reinventing medical imaging with machine learning on AWS

It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 3, 2020 | 6:45 AM – 7:15 AM EST

Making healthcare more personal with MetroPlus Health

COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar

Healthcare Public Sector

DEC 3, 2020 | 8:15 AM – 8:45 AM EST

Securing protected health information and high-risk datasets

Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar

Healthcare Life Sciences

DEC 3, 2020 | 9:45 AM – 10:15 AM EST

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 

In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More

Add To Calendar

Public Sector Partner Solutions for Business

DEC 3, 2020 | 10:30 AM – 11:00 AM EST

How Vyaire uses AWS analytics to scale ventilator production & save lives

When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar

Analytics Healthcare

DEC 3, 2020 | 4:15 PM – 4:45 PM EST

Productionizing R workloads using Amazon SageMaker, featuring Siemens

R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Enterprise/Migration

DEC 3, 2020 | 6:15 PM – 6:45 PM EST

Accelerating the transition to telehealth with AWS

Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar

Healthcare Public Sector

Friday, December 4

DEC 4, 2020 | 12:15 AM – 12:45 AM EST

Productionizing R workloads using Amazon SageMaker, featuring Siemens

R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Enterprise/Migration

DEC 4, 2020 | 2:15 AM – 2:45 AM EST

Accelerating the transition to telehealth with AWS

Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar

Healthcare Public Sector

DEC 4, 2020 | 8:15 AM – 8:45 AM EST

Productionizing R workloads using Amazon SageMaker, featuring Siemens

R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Enterprise/Migration

DEC 4, 2020 | 10:15 AM – 10:45 AM EST

Accelerating the transition to telehealth with AWS

Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar

Healthcare Public Sector

Tuesday, December 8

DEC 8, 2020 | 2:30 PM – 3:00 PM EST

How Erickson Living built a COVID-19 outbreak management solution

As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar

Analytics Life Sciences

DEC 8, 2020 | 5:30 PM – 6:00 PM EST

Rapidly deploying social services on Amazon Connect

Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar

Public Sector Business Apps (including Connect)

DEC 8, 2020 | 5:30 PM – 6:00 PM EST

Improving data liquidity in Roche’s personalized healthcare platform

Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar

Life Sciences Artificial Intelligence & Machine Learning

DEC 8, 2020 | 10:30 PM – 11:00 PM EST

How Erickson Living built a COVID-19 outbreak management solution

As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar

Analytics Life Sciences

Wednesday, December 9

DEC 9, 2020 | 1:30 AM – 2:00 AM EST

Rapidly deploying social services on Amazon Connect

Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar

Public Sector Business Apps (including Connect)

DEC 9, 2020 | 1:30 AM – 2:00 AM EST

Improving data liquidity in Roche’s personalized healthcare platform

Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar

Life Sciences Artificial Intelligence & Machine Learning

DEC 9, 2020 | 6:30 AM – 7:00 AM EST

How Erickson Living built a COVID-19 outbreak management solution

As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar

Analytics Life Sciences

DEC 9, 2020 | 9:30 AM – 10:00 AM EST

Rapidly deploying social services on Amazon Connect

Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar

Public Sector Business Apps (including Connect)

DEC 9, 2020 | 9:30 AM – 10:00 AM EST

Improving data liquidity in Roche’s personalized healthcare platform

Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar

Life Sciences Artificial Intelligence & Machine Learning

DEC 9, 2020 | 10:30 AM – 11:00 AM EST

BlueJeans’ explosive growth journey with AWS during the pandemic

Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar

Telecommunications Media & Entertainment

DEC 9, 2020 | 5:15 PM – 5:45 PM EST

Using AI to automate clinical workflows

Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 9, 2020 | 5:45 PM – 6:15 PM EST

Building patient-centric virtualized trials

As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar

Life Sciences Healthcare

DEC 9, 2020 | 6:30 PM – 7:00 PM EST

BlueJeans’ explosive growth journey with AWS during the pandemic

Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar

Telecommunications Media & Entertainment

Thursday, December 10

DEC 10, 2020 | 1:15 AM – 1:45 AM EST

Using AI to automate clinical workflows

Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 10, 2020 | 1:45 AM – 2:15 AM EST

Building patient-centric virtualized trials

As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar

Life Sciences Healthcare

DEC 10, 2020 | 2:30 AM – 3:00 AM EST

BlueJeans’ explosive growth journey with AWS during the pandemic

Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar

Telecommunications Media & Entertainment

DEC 10, 2020 | 9:15 AM – 9:45 AM EST

Using AI to automate clinical workflows

Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 10, 2020 | 9:45 AM – 10:15 AM EST

Building patient-centric virtualized trials

As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar

Life Sciences Healthcare

DEC 10, 2020 | 2:30 PM – 3:00 PM EST

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More

Add To Calendar

Storage Business Apps (including Connect)

DEC 10, 2020 | 4:00 PM – 4:30 PM EST

Healthcare executive outlook: Accelerating transformation

Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is working

… Learn More

Add To Calendar

Healthcare Life Sciences

DEC 10, 2020 | 10:30 PM – 11:00 PM EST

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More

Add To Calendar

Storage Business Apps (including Connect)

Friday, December 11

DEC 11, 2020 | 12:00 AM – 12:30 AM EST

Healthcare executive outlook: Accelerating transformation

Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is worki

… Learn More

Add To Calendar

Healthcare Life Sciences

DEC 11, 2020 | 6:30 AM – 7:00 AM EST

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More

Add To Calendar

Storage Business Apps (including Connect)

DEC 11, 2020 | 8:00 AM – 8:30 AM EST

Healthcare executive outlook: Accelerating transformation

Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is worki

… Learn More

Add To Calendar

Healthcare Life Sciences

Tuesday, December 15

DEC 15, 2020 | 1:00 PM – 1:30 PM EST

Intelligent document processing for the insurance industry

Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 15, 2020 | 3:00 PM – 3:30 PM EST

AWS Partners driving innovation amidst COVID-19

This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More

Add To Calendar

Global Partner Summit (GPS) Session

DEC 15, 2020 | 9:00 PM – 9:30 PM EST

Intelligent document processing for the insurance industry

Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 15, 2020 | 11:00 PM – 11:30 PM EST

AWS Partners driving innovation amidst COVID-19

This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More

Add To Calendar

Global Partner Summit (GPS) Session

Wednesday, December 16

DEC 16, 2020 | 5:00 AM – 5:30 AM EST

Intelligent document processing for the insurance industry

Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 16, 2020 | 7:00 AM – 7:30 AM EST

AWS Partners driving innovation amidst COVID-19

This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More

Add To Calendar

Global Partner Summit (GPS) Session

DEC 16, 2020 | 11:45 AM – 12:15 PM EST

Simplify healthcare compliance with third-party solutions

Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compli

… Learn More

Add To Calendar

Marketplace Healthcare

DEC 16, 2020 | 12:45 PM – 1:15 PM EST

An introduction to healthcare interoperability and FHIR Works on AWS

Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 16, 2020 | 1:15 PM – 1:45 PM EST

Achieving healthcare interoperability with FHIR Works on AWS

The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 16, 2020 | 6:00 PM – 6:30 PM EST

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar

IoT Manufacturing

DEC 16, 2020 | 7:45 PM – 8:15 PM EST

Simplify healthcare compliance with third-party solutions

Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compli

… Learn More

Add To Calendar

Marketplace Healthcare

DEC 16, 2020 | 8:45 PM – 9:15 PM EST

An introduction to healthcare interoperability and FHIR Works on AWS

Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 16, 2020 | 9:15 PM – 9:45 PM EST

Achieving healthcare interoperability with FHIR Works on AWS

The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar

Public Sector Healthcare

Thursday, December 17

DEC 17, 2020 | 2:00 AM – 2:30 AM EST

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar

IoT Manufacturing

DEC 17, 2020 | 3:45 AM – 4:15 AM EST

Simplify healthcare compliance with third-party solutions

Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compliance

… Learn More

Add To Calendar

Marketplace Healthcare

DEC 17, 2020 | 4:45 AM – 5:15 AM EST

An introduction to healthcare interoperability and FHIR Works on AWS

Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 17, 2020 | 5:15 AM – 5:45 AM EST

Achieving healthcare interoperability with FHIR Works on AWS

The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar

Public Sector Healthcare

DEC 17, 2020 | 10:00 AM – 10:30 AM EST

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar

IoT Manufacturing

DEC 17, 2020 | 11:15 AM – 11:45 AM EST

Share information by removing language barriers with Amazon Translate

In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

DEC 17, 2020 | 7:15 PM – 7:45 PM EST

Share information by removing language barriers with Amazon Translate

In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

Friday, December 18

DEC 18, 2020 | 3:15 AM – 3:45 AM EST

Share information by removing language barriers with Amazon Translate

In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

Friday, December 18

DEC 18, 2020 | 3:15 AM – 3:45 AM EST

Share information by removing language barriers with Amazon Translate

In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.

Add To Calendar

Artificial Intelligence & Machine Learning Healthcare

Life Sciences sessions

Bookmark this blog and check back for direct links to each session and add to your re:Invent schedule as soon as the session catalog is released:

LFS201: Life Sciences Industry: Executive Outlook
Learn how AWS technology is helping organizations improve their data liquidity, achieve operational excellence, and enhance customer engagement.

LFS202: Improving data liquidity in Roche’s personalized healthcare platform
Learn how Roche’s personalized healthcare platform is accelerating drug discovery and transforming the patient journey with digital technology.

LFS302: AstraZeneca genomics on AWS: from petabytes to new medicines
Learn how AstraZeneca built an industry leading genomics pipeline on AWS to analyze 2 million genomes in support of precision medicine.

LFS303: Building patient-centric virtualized trials
Learn how Evidation Health architects on AWS to create patient-centric experiences in decentralized and virtual clinical trials.

LFS304: Streamlining manufacturing and supply chain at Novartis
Learn how Novartis is creating real-time analytics and transparency in the pharma manufacturing process and supply chain to bring innovative medicines to market.

LFS305: Accelerating regulatory assessments in life sciences manufacturing
Learn how Merck leveraged Amazon Machine Learning to build an evaluation and recommendation engine for streamlining pharma manufacturing change requests.

Other related sessions of interest:

ENT203: How BMS automates GxP compliance for SAP systems on AWS

GPS211: AWS Partners driving innovation amidst COVID-19

HLC203: Securing Personal Health Information and High Risk Data Sets

WPS202: Transform research environments with Service Workbench on AWS

AIM310: Intelligent document processing for healthcare organizations

Healthcare Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned for the Healthcare industry with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. See how AWS experts and talented members of the Healthcare industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Healthcare attendees looking to get the most out of their experience, follow these steps:

• Register for re:Invent.
• Take a look at all of the Healthcare sessions available, as well as lots of other information and additional activities, in our curated Healthcare Attendee Guide coming soon!
• Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Healthcare at re:Invent 2020

AWS is the trusted technology partner to the global healthcare industry. For over 12 years, AWS has established itself as the most mature, comprehensive, and broadly adopted cloud platform and is trusted by thousands of healthcare customers around the world—including the fastest-growing startups, the largest enterprises, and leading government agencies. The secure and compliant AWS technology enables the highly regulated healthcare industry to improve outcomes and lower costs by providing the tools to unlock the potential of healthcare data, predict healthcare events, and build closer relationships with patients and consumers. The healthcare track at re:Invent 2020 will feature customer-led sessions focused on these each of these critical components, accelerating the transformation of healthcare.

Healthcare sessions

Learn more and bookmark each Healthcare session:

HCL201: Healthcare Executive Outlook: Accelerating Transformation
Learn how AWS is working with industry leaders to increase their pace of innovation, unlock the potential of their healthcare data, help predict patient health events, and personalize the healthcare journey for their patients, consumers, and members.

HLC202: Making Healthcare More Personal with MetroPlus Health
Learn how MetroPlus Health leveraged AWS technology to quickly build and deploy an application that personally and proactively reached out to its members during a time of critical need.

HLC203: Securing Personal Health Information and High Risk Data Sets
Learn how Arcadia developed a HITRUST CSF Certified platform by leveraging AWS technology to enable the secure management of data from over 100 million patients.

HLC204: Accelerating the Transition to Virtual Care with AWS
Learn how MedStar Health developed and deployed two call centers in less than week that are supporting more than 3,500 outpatient telehealth sessions a day.

WPS202: Transform research environments with Service Workbench on AWS
Learn how Harvard Medical School is using AWS to procure and deploy domain-specific data, tools, and secure IT environments to accelerate research.

WPS209: Reinventing medical imaging with machine learning on AWS
Learn how Radboud University Medical Center uses AWS to power its machine learning imaging platform with 45,000+ registered researchers and clinicians from all over the world.

WPS211: An introduction to healthcare interoperability and FHIR Works on AWS
Learn about AWS FHIR Works, an open-source project, designed to accelerate the industries use of the interoperability standard, Fast Healthcare Interoperability Resources (FHIR).

WPS304: Achieving healthcare interoperability with FHIR Works on AWS
Learn how Black Pear Software leveraged AWS to build an integration toolkit to help their customers share healthcare data more effectively.

Extras you won’t want to miss out on!

LFS201: Life Sciences Industry: Executive outlook

LFS202: AstraZeneca genomics on AWS: From petabytes to new medicines

LFS303: Building patient-centric virtualized trials

AIM303: Using AI to automate clinical workflows

AIM310: Intelligent document processing for the insurance industry

INO204: Solving societal challenges with digital innovation on AWS

ZWL208: Using cloud-based genomic research to reduce health care disparities

GPS211: AWS Partners driving innovation amidst COVID-19

Read Full Post »

e-Proceedings 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 in Boston

Posted in Advanced Computing Platform, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence in Medicine - Applications in Therapeutics, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Conference Coverage with Social Media on March 26, 2020| Leave a Comment »

e-Proceedings 19^th Annual Bio-IT World 2020 Conference, October 6-8, 2020 Boston

https://bio-itworld.pathable.co/meetings/virtual/3T3SuWw9J2Bceei9s

 Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN

 

Tweets & Retweets by @pharma_BI and @AVIVA1950 at #BioIT20, 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 in Boston

Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/10/08/tweets-retweets-by-pharma_bi-and-aviva1950-for-bioit20-19th-annual-bio-it-world-2020-conference-october-6-8-2020-in-boston/

October 6, 2020

PLENARY KEYNOTE –

10:15 am ET – NIH’s Strategic Vision for Data Science

• 

  Susan Gregurick

  NIH

  Associate Director for Data Science

• Connected Data Ecosystem – Project is FAIR
• Data shareable
• NIH – agenda on data: diverse sets of data: Images of MRI, cells, of organs, of communities,
• Share images and link it to tables
• METADATA 34PB enable search – moving Data to clouds for Large-Scalable Analysis
• Sequence Read Archive (SRA) – DNA seq.
• COVID-19 from around the World SRA in Cloud Partnerships enabled
• Open Science – enhance SW tools for making research cloud-ready
• NIH has 12 Centers: Genomics, Neuro-imaging
• SCH – Smart & Connected Health
• IT, Sensor system hardware, effective usability, medical interpretation, Transformative data Science
• Cancer, Alzheimer’s, Genomics, Medical Imaging, Brain circuits,
• Coding it Forward: Students come to NIH Virtually from home to join CIVIL DIGITAL FELLOWSHIP
• COVID-19: repositories of data for researches:

1. Treatment for Interventions
2. Long term Sequelae
3. Clinical platforms: BigData Catalyst, Allow US, ADSO, National COVID Cohort
4. Across platforms: workflow after RAS August Deploy: Passport for researchers to access data faster, Privacy-Preserving Tokens, Interoperability across clinical COVID data bases
5. Metadata super rich to link to other new data sources is a challenging issue to solve across studies

Scott Parker

Sinequa Corp

Director of Product Marketing

• Disconnect between R&D & IT
• Intelligence search Applications for sensitive information: Sinequa is a leader
• shares one index cost for document go down & productivity increases

Rebecca Baker

NIH OD

Dir HEAL Initiative

• END ADDICTION Project – NIH HEAL Initiative: 20 NIH collaborating on Studies
• National Overdose Deaths overdose opioid drugs – synthetic Fentanyl
• Heroin, Cocaine, Methamphetamine
• During COVID Overdose increased during the pandemic
• Increase in drug use overall and 67% of Fentanyl
• Chronic Pain: Daily severe pain: can’t go to work – 25 Million
• $500 Million/year Sustained Research Investment 25+ HEAL Research Programs
• HEAL Initiative: Pain management, Translating research, New presention, enhance outcomes for affected newborns, novel medications options Pre-clinical translational research in Pain management
• Improving treatments for opioid misuse & addiction
• Opioid disorder people do not receive treatment: justice community, collaborative, ER, pregnant mothers
• Medication-based treatment – do not stay long enough to achieve long-term recovery
• People experience Pain differently: Muscular, neurological, : Biomarkers, endpoints, signatures, test non-addictive treatments for specific pains
• Pain control balance of risks of long-term opioid therapy
• HEAL Research – infant born after exposure to opioids in utero affect brain growth, born with withdrawal syndromes
• Diversity of Data under HEAL Initiative –>> Harmonize the data
• Common Data Elements in HEAL Clinical Research in Pain Management
• CORE CDE & Supplemental CDE
• Making HEAL Data FAIR: Findable, Accessible, Interpretable, Reusable
• LINK HEAL data with communities studies, predict behaviours
• Data sharing made available to the public
• HEAL Data Lifecycle
• effect of change due to change in dosage used – if dat is not collected – then we are not able to explore the relationships
• Use the data to advance research beyond the current understanding of the problem
• #NIHhealthInitiative

 

Ari Berman

BioTeam Inc

Chief Executive Officer

• Distributed Questions from the Audience to the speakers

10:00 AM – 11:25 AM EDT on Tuesday, October 6

How to Hold on to Your Knowledge in an Agile World

Etzard Stolte

Roche Pharma

Global Head

October 7, 2020

The Chicagoland COVID-19 Commons: A Regional Data Commons Powering Research to Support Public Health Efforts

• 

  Matthew Trunnell

  VP & Chief Data Officer

9:00 AM – 9:20 AM EDT on Wednesday, October 7

• Seattle & COVID – samples from Seattle Flu Study
• Public Health Practice vs Research – Data from Human Subjects: Avoid delute the control
• Chicagoland COVID-19 Data Commons – in Chicago

1. Neighborhood level in Chicago
2. common data model
3. power efforts Predictive modeling : Case rate Total confirmed cases, Death cases
4. Legal agreement of the Consortium
5. https://chicagoland.pandemic

• Commons – resources held in commons non-for profit
• Data Commons: cloud based SW platforms that are co-located data, computing infrastructure and applications
• Level 1: Basic, Level 2: Repeatable, Level 3: Governance Level4: Interoperability Level 5: Sustainable
• COVID-19 Data Common: Public health authorities collects data – nor available to Research community
• Research community need access to Public health authorities
• Regional COVID-19 Data Commons: Reasons: Public health decision is LOCAL but specific to the Region
• Fund raising in the communities
• Data 1: Clinical Data for Health care Summary of incidence – Signals of ethnic dependencies and co-morbidities

1. Safe harbor: removal of 18 identifiers
2. Expert Determination

• Data 2: Public Data: Environmental,
• Data 3: Resident-Reported Data on iPhones: multiple languages supported early reports of people feeling unwell

CompBio: An Augmented Intelligence System for Comprehensive Interpretation of Biological Data

Richard Head

Washington Univ

Prof & Dir Genome Technology Access Ctr

9:20 AM – 9:40 AM EDT on Wednesday, October 7

• Formating, data scrubbing,
• Replace data fabric with simplified version
• create “Memory Model” Machine learning does classification of patterns
• dimensions are the variables
• “Hyper-dimensional – ingestions of abstracts and articles
• Example; IL^: Aggregate Memories to create a NORMALIZED Aggregate Memory
• Relationships explored
• Complex Knowledge Patterns Generated by the PCMM: Compared Utilization
• Augmented AI System: Combination PCMM with AI
• Literature mining CompBio
• Evidence of Utility: PCMM – Accepted or Published Research Leveraging PCMM Applications
• Example 1: Cell Metabolism CompBio – A person formulate hypothesis
• Example 2: Analysis of RNA-Seq a rare mutational subtype of GBM

1. Hypothesis –>> BioExplorer –>> Multiple relations revealed
2. Example 3: Animal Models to Human Disease: CompBio – Crohn’s Assertion Engine

Summary – Augmented AI Platform for Biological DIscovery

• PCMM – Memory modle – hyperdimensional
• AAI Infrastructure
• Knowledge map libraries
• In development Medical Discoveries

PercayAI Team – commercial Development

Kingdom Capital

 

Precision Cancer Medicine

• 

  Jeffrey Rosenfeld

  Rutgers Univ

  Asst Prof

9:40 AM – 10:00 AM EDT on Wednesday, October 7

• Cancer Classification: Shift from Anatomy/History of Molecular Etiology
• Chronic Myeloenous Leukemia  – Gleevec
• Type cancer seq:

 

1. Hereditary cancer sequencing – BRCA
2. Tumor cancer sequencing

• Panel Sizes – 500-1000x – the bigger the panel – more computational time more data need be investigated

1. Hotspot Panels,
2. Gene Panels,
3. Exomes

• Cell free DNA Testing – Liquid biopsy

1. Apoptosis
2. Necrosis

• FoundationONE
• Patient Results: ALL mutations found, Mutation Burden,
• Gene EGFR – no mutation
• For every Mutation what Therapy is recommended for approved drugs
• Clinical Trials for the mutations
• VARIANTS of unknown significance
• WORKFLOW: many MDs send sample get 38pps report
• Genomic Classification and Prognosis in AML: Mutations subset and therapies available
• Paradigm Shift in Classification

1. 2013 – Lung Adenocarcinoma <<<- –
2. 2011 – another cancer

 

mTOR System: A Database for Systems-Level Biomarker Discovery in Cancer

• 

  Iman Tavassoly – CANCELLED

  C2i Genomics

  Physician Scientist

10:20 AM – 10:40 AM EDT on Wednesday, October 7
Add to Calendar

mTOR system is a database I have designed for exploring biomarkers and systems-level data related to mTOR pathway in cancer. This database consists of different layers of molecular markers and quantitative parameters assigned to them through a current mathematical model. This database is an example of merging systems-level data with mathematical models for precision oncology.

FAIR and the (Tr)end of Data Lakes

• 

  Kees Van Bochove

  The Hyve

  Founder & Owner

10:20 AM – 10:40 AM EDT on Wednesday, October 7

Normalizing Regulatory Data Using Natural Language Processing (NLP)

• 

  Qais Hatim, Dr.

  FDA CDER

  Visiting Assoc

David Milward

Linguamatics

Senior Director, NLP Technology

10:40 AM – 11:00 AM EDT on Wednesday, October 7

• ML focus on Disease
• NLP – different words have same meanings, different expression same meaning, grammer & Meaning
• Normalizes output

1. Disease
2. Genes
3. Dates
4. Mutations

• Transform Unstructured into structured
• Identifying Gaps in adverse events Labelling: Pain and Opioids
• Improve drug safety
• ChemAxon

Supplemental Approval Letters

Coding for Adverse events: “derived values of possible interest”

• Use of Prominent Terminologies used at the FDA: UNII – Translation into ANSI tesaurus standard
• Matching to the Variation found within Real Text: synonyms
• Using ML for Normalization in Disease Context
• Deep Learning PRE-TRAINING APPROACH for annotated date = supervised learning
• A set of rules to handle overlapping entities
• normalized the amp extracted from concepts
• BERN and Terminologies: BioBERN, PubMed Central, PubMed Articles
• NER – Named Entity Recognition
• Evaluation of the Approach

Conclusions

NLP, ML, Hybrid methods, Terminology +ML methods

Building an Artificial Intelligence-Based Vaccine Discovery System: Applications in Infectious Diseases & Personalized Neoantigen-Related Immunotherapy for Treatment of Cancers

• 

  Kamal Rawal

  Amity Univ

  Assoc Prof

10:40 AM – 11:00 AM EDT on Wednesday, October 7

• Classification of proteins
• Data Collection
• Feature Selection – Most important from 1447 features
• Deep learning Model: Vaxi-DL: Layers, compilation
• Overfitting Model strategy
• Balancing Imbalanced
• Hyper parameter tuning: Internal parameter of the model
• Stratified K-Fold Training and Validation
• Ensembling Approach: many weak classifier to create a STRONG Classifier
• ROC Curve: Ensemble by Consensus
• Before and after calibration
• Benchmarking the system: Vaxi-DL Ensemble by Average vs by Consensus
• SYSTEM developed: Type protein – find results
• Rare disease CHARGE Syndrome was used for validation
• Application to COVID-19 – Methodology
• Application on Cancer: Which peptide can be used as antigen for prediction of immunogenic peptides

 

Using GPU Computing to Evaluate Variant Calling Strategies

• 

  George Vacek

  NVIDIA Corp

  Sequencing Strategic Development

• 

  Eriks Sasha Paegle

  Dell EMC

  Senior Business Development Manager

11:15 AM – 11:30 AM EDT on Wednesday, October 7

• Navidia: 100 Genomes Cohort generated at NY Genome Center  NHGRI
• Navidia Parabricks mentioned AZURE
• Dell EMC: Test environment: Dell Technology Cloud Storage for Multi-Cloud: resources across GCU, AWS, Azure in Northern Virginia regions
• Multi-Cloud ease of use: without Multi-cloud vs with Faction multi-clouds
• Ease of use
• Deep Averaging Network (DAN)
• NVIDIA CLARA PARABRICK TOOLKIT: Short & Long read, Deep learning, Data Analytics, ML
• Reference applications – host of customized applications, 3rd Party App, Libraries
• GPU (Genomics PUs) – Drop in tools for Somatic Pipelines : Clara Parabricks v3.5
• Partnership of NVIDIA and Petagene announced at BioIT20 – NGS Data compretion
• Petagene technology allows lossless compression reduce storage costs
• Project with Sanger Institute – Optimizing Muto-graph Identification
• completed run in 24 hours instead 31 days
• Parabricks is a joint project Dell/EMC and NVIDIA

PLENARY KEYNOTE: Game On: How AI, Citizen Science, and Human Computation Are Facilitating the Next Leap Forward

12:30 PM – 1:55 PM EDT on Wednesday, October 7

• 

  Allison Proffitt

  BioIT World & Diagnostics World

  Editorial Dir

Seth Cooper

Northeastern Univ

Asst Prof

• Foldit – Scientific discovery using video games in the domain of protein structures and folding
• Combine Human with machine
• Score based on competition among players for higher score and collaboration in groups
• Problem: Chemistry give input.
• Puzzle available for one week on the Internet, games ongoing,
• Solution analysis – continually IMPROVE the structure of Protein folding
• Foldit Tutorials offered online
• Player accomplishments: Articles by scientists ,
• development of algorithms discovery
• Electron Density fitting
• Enzyme re-design
• de novo Protein Design – named authors on a paper – scientific process
• Future Work: Coronovirus Spike protein
• Small molecule design
• narrative
• virtual reality – 3D protein structure for manipulation
• htp://Fold.it/Educator Mode
• htp://Fold.it/standalone
• http://fold.it/
• seth.cooper@gmail.com

Lee Lancashire, CIO

Cohen Veterans Bioscience – not for profit – advancing Brain health

• Biotyping and stratification
• Biomarkers
• Omics data
• All meet in the Common – Brain Commons: Clinician, Geneticist, Scientist, Bioinformatician, R Studio, Python, Jupyterhub
• Multidimensional Biomarkers in Multiple Sclerosis

 

Pietro Michelucci

Human Computation Institute

Director

• Why machine can’t tackle AI on their own and AI can’t do Precision Medicine on their own
• young people more than others N of 1 – Precision Mediicne
• Scandinavians and Russians are immune
• AI & Precision Medicine: can’t solve the complexity of messy data vs big data
• Messy data: heterogeneous multidimensional, to many combinations to explore, select which combination to explore vs let the machine generate all the combination and do analysis on all and discover PATTERN
• Causal vs spurious
• Logical reasoning, right brain abstract and short cuts – Human brain does routinely
• Human do better on context: Not all info is in pixels such as context
• #ADS – SBIR suspected the hypothesis to be tested
• improving crowd wisdom methods: 20 input by different people PLUS machine
• combine crowd answers with machine faster and improved accuracy
• Machine has no intuition – machine bias of Human and of machine is similar
• Wisdom of Crowd: Bootstrapping hybrid Intelligence: CIVIUM
• bit.ly/civiumintro

 

 

Jerome Waldispuehl

McGill Univ

Assoc Prof

• visualization of nucleotide – tools for
• http://phylo.cs.mcgill.ca
• GAME: Phylo DNA Puzzles: Goal 202, Score, Top Score
• Whole-genome multiple
• Phylo: 350,000 participants, 1MM solutions Improve 40 to 95% computer alignments
• education & science outreach – reach out to the Public
• Borderlands Science + game designers: 1MM participants 50MM solutions
• Joint initiative with a major science project
• Improvement of 16S rRNA
• MMOS company in Science games

Towards AI-Guided Cell Profiling of Drugs with Automated High-Content Imaging

Ola Spjuth

Uppsala Univ

Professor

2:10 PM – 2:30 PM EDT on Wednesday, October 7

• Accelerate drug discovering using AI automation in collaboration with AstraZeneca
• Closed-loop (autonomous) experimentation
• collect the best data at the minimal cost
• Active learning: query active learning model
• Exploitation [best predictions from given data] vs Exploration
• Automation in Life Science: micro-plate, stack of micro-plates
• Robot scientist: come out with hypothesis and conduct research
• high-throughput biology: Robots vs Disease
• Cell painting: Imaging with multiplexed dyes: genetic or chemical perturbations
• classify images into biological mechanisms
• combinations of toxicants
• A discovery engine: Toxicity, Efficacy, mechanisms combinations
• Automating our cell-based lab: fixed setup
• Open source lab automation suite: Github https://github.com/pharmbio/imagedb
• Dealing with large scale data [TensorFlow]
• STACKn.com – AI modeling Life cycle
• HASTE: Hierarchical analysis of Spacial and Temporal
• https://pharmb.io

Advanced Imaging and AI Technologies Providing New Image and Data Analysis Challenges and Opportunities

Richard Goodwin

AstraZeneca

Dir & Head of Imaging & AI

2:30 PM – 2:50 PM EDT on Wednesday, October 7

AstraZeneca is empowering its scientists to see the complexity of a disease in unprecedented detail to enable effective development and selection of new medicines. This is enabled though the use of an extensive range of cutting-edge imaging technologies that support studies into the efficacy and safety of drugs through the R&D pipeline. This presentation will introduce the range of novel in vivo and ex vivo imaging technologies employed, describe the data challenges associated with scaling up the use of molecular imaging technologies, and address the new data integration and mining challenges. Novel computational methods are required for large cohort imaging studies that involve tissue based multi-omics analysis, which integrate spatial relationships in unprecedented detail.

• Small molecule – not suitable for complex diseases
• focus on quality vs quantity
• compound for commercial value
• right safety
• Imaging supports R&D: Molecular, medical, big data and AI
• convergence of ML for decision making
• Spatial imaging: morphology
• Multiplex imaging like MRI
• Multimodal analysis: tissue data and invivo holistic understanding of drug delivery
• spacial transcriptomics proteomics: imaging platforms in R&D
• AZ invest in imaging technologies already impacting projects: AI-empowered imaging delivering subcellular resolution
• Mass Spec Imaging (MSI) – ex-vivo imaging techniques- spatial distribution of molecular
• cartography of cancer: Drug metabolite distribution – NEW understanding of disease and drug distribution in tissue
• DATA: digitization, integration, analysis, exploration
• Digital pathology and beyond – AI Image Analysis – AI outperform pathololigst and radiologists
• Data volume and dimensionality challenge and opportunity
• Data volume and dimensionality: complete image
• AZ Oncology – disease is understood for drug discovery using Imaging technology

PANEL: Framework and Approach to Unlock the Potential of Quantum Computing in Drug Discovery

• 

  Brian Martin

  AbbVie Inc

  Research Fellow & Head

Philipp Harbach

Merck KGaA

Head of In Silico Research in Germany

• chemistry and manufacturing with QC – end user in Pharmaceutical
• VC at Merck ask expert in Merck to guide investment of Merck in QC
• 50 people across Merck [three areas at Merck [Pharmaceutics, Animal Health, Diagnostics]

Celia Merzbacher

SRI Intl

Assoc Dir Quantum Economic Dev Consortium (QEDC)

• Methodology from Pistoia to be used in QC
• QC R&D developed in parallel
• Simulation of all the components is possible

John Wise

Pistoia Alliance Inc (2007)

We are a global, not-for-profit members’ organization working to lower barriers to innovation in life science and healthcare R&D through pre-competitive collaboration.

Consultant

• How Pharmaceutical Industry can benefit from quantum computing
• 9 of 10 big Pharma are members of the Pistoia Alliance
• IP created on specifications

 

Zahid Tharia

Pistoia Alliance Inc

Consultant

• Barriers to adoption of quantum computing (QC) in Pharma is training of staff and skills in the IT aspects of QC

3:10 PM – 4:00 PM EDT on Wednesday, October 7

In 2019, major life sciences companies mobilized to form a pre-competitive, collaborative quantum computing working group (QuPharm) and delineate a framework and approach to accelerate realizing the potential of quantum acceleration in drug discovery. Learn from industry thought leaders on how to valuate and map problems into quantum algorithms, set up organizations to enable and scale quantum computing pilots and establish effective cross-industry, tech, and start-up collaborations.

TRACK 11: BIOINFORMATICSTRACK 12: PHARMACEUTICAL R&D INFORMATICS

Session Wrap-Up Panel Discussion

Etzard Stolte, PhD

Roche Pharma

Global Head

• no official policy
• 2020 it become important to be mentioned by management as a potential use in automation
• continual updates needed – it is manual and a disillusion without a business case
• Roche try to commodatized tools in AI as Classifiers, automation,

Samiul Hasan

GlaxoSmithKline

Scientific Analytics and Visualization Director

• AI is perceived as having potential to take off on its own
• POC – demonstrate the vlaue
• Proof of Concept – Semantic report – a story vs one off
• demonstration of value is needed and is continuous

 

 

Bin Li

Millennium The Takeda Oncology Co

Dir Computational Biology & Translational Medicine

• ML community at Takeda
• Positive to have, how successful not much yet – not used much yet
• some models are pretty good do not need improvement

Jens Hoefkens

Accenture

Industry Principal Director

• Future of AI as support to the Human intuition vs replacement of humans
• automation like pathology classification
• Machine and Human working together – not as maker of decisions in clinical settings
• POC cycle prevent production conversion
• where is the highest value for production and deploy with scale
• AI Assisted to sift Genomics data
• BERT term extraction from Google technology to make sense of data assist the user
• ML
• RPA – Robotic concept extraction – 80% accuracy needed by scientists

4:00 PM – 4:20 PM EDT on Wednesday, October 7

• PANEL

October 8, 2020

Trends from the Trenches

Kevin Davies, PhD

CRISPR Journal

Exec VP & Exec Editor

Timothy Cutts

Wellcome Sanger Institute

Head

• Collaborations with scientists in subSahara
• pay for data analysis – ownership issues
• in UK 6 Labs for the entire countries: all send the data to Wellcome Sanger Institute for analysis
• Metadata is the problem – coordination of each of the 6 labs to send the metadata created problems

 

• 

  Cindy Crowninshield

  Cambridge Healthtech Institute

  Executive Event Director

Vivien Bonazzi

Deloitte Consulting LLP

Managing Dir & Chief Biomedical Data Scientist

• How organizations use bioscience data
• Data Ecosystem: Hardware and software: Cloud and other options
• Operationalize the two trends:

1. Platforms: End to end solutions resulting in SILOS, systems are native: data ingestions
2. Data Commons: Open arch, open source – integration and interdependence issues

• Biomedical Agencies in NIH various Organizations in the Private sector: Sharing data must be more effective
• IT, Data Science, Management – COVID – reduced barriers
• Leadership: Different voices from different people
• Data strategies & Governance not the whole but small pieces , incentives to share data

Chris Dagdigian

BioTeam Inc

Sr Dir

• 10th Anniversary to Trends from the Trenches
• IT infrastructure changes
• Research IT:

1. Genomics & BioInformatics
2. Image-based data acquisition and analysis: CryoEM, 3D microscopy, fMRI image analysis
3. ML and AI – GPU FPGAs, neural processors: Drive in organizations: bottom up
4. Chemistry & Molecular Dynamics
5. Storage and exploitation of data for insights
6. 2020 Hype vs Reality
7. Scientific Data: managing and understanding, data movement, federated/access
8. Big Data: data storage, management & governance standards vs human curated data
9. IT needs guidance and decisions from Science Team
10. Culture change for joint management by Science & IT: data fidelity, attribution, allocation top down
11. NERSC File System quotas & Purging overviewSilos & So
12. Petabytes of open access data, collaborative research resources: Data rich environments
13. Data Lakes: Gen3 Data Commons
14. Data hygiene:metadata is Science side vs IT
15. Biased Data: Model & Data Bias

• Failed Predictions:

1. Compilers matter again – not True
2. CPU benchmarking is back – WRONG
3. AMD vs Inter arm64 vs both
4. Policy driven auto-tiering storage – wrong, USER self-service for tiering, movement and archive decision. Let researchers tier/move/archive based on Project, Experiment or Group
5. Single storage namespace – Wrong: Data intensive science: scientists must do some IT jobs themselves

Kjiersten Fagnan

Lawrence Berkeley Natl Lab

CIO

• Genome Project of DOE
• Data management with other agencies
• COVID: Collaborations, breaking down barriers, small labs and big labs ALL generate data and sharing
• that collaboration is needed regardless of COVID – not happen
• If twoo big one lab can’t handle it all
• Funding and training does not support the Collaborations because next round of funding depend on individual publications – which requires silos
• Data cleaning and data management:Standards are annoying and painful – not needed for publishing the results as soon as possible – just that someone else will be able to use it
• Facebook have hundred of curators – the curation of scientific data requires same hunsrands od curators that are SCIENTISTS and Data scientists

Matthew Trunnell

Pandemic Response Commons, Seattle

VP & Chief Data Officer

• Data commons for intra- and inter-mural data sharing
• ML is needed for Data commons
• Progress in FAIRness, NIH efforts driven by Susan Gregory across NIH all centers
• Large amount of B-to-B Data sharing UBER sharing with a jurisdiction they operate
• SNOWFLAKES – new cloud technology
• COVID – plays an accelerator
• Cancer vs COVID – transfer knowledge from COVID to Cancer

9:00 AM – 10:40 AM EDT on Thursday, October 8

The “Trends from the Trenches” will celebrate its 10th Anniversary at Bio-IT! Since 2010, the “Trends from the Trenches” presentation, given by Chris Dagdigian, has been one of the most popular annual traditions on the Bio-IT Program. The intent of the talk is to deliver a candid (and occasionally blunt) assessment of the best, the worthwhile, and the most overhyped information technologies (IT) for life sciences. The presentation has helped scientists, leadership, and IT professionals understand the basic topics related to computing, storage, data transfer, networks, and cloud that are involved in supporting data-intensive science. In 2020, Chris will give the “Trends from the Trenches” presentation in its original “state-of-the-state address” followed by guest speakers giving podium talks on relevant topics. An interactive Q&A moderated discussion with the audience follows. Come prepared with your questions and commentary for this informative and lively session.

• PLENARY
• PANEL

Q&A

• Project vs enterprise – Sequencing for internal research vs for clients’ data
• Tension in governmental agencies – no robust solutions: IT, Science, Management
• different Use cases need different infrastructure: HW & SW: Storage and data exploration
• Data Lakes: rule base, enterprising – training is an issue in organizations
• Management, Scientists, IT in enterprises – terra byte of storage, budgets issues, conversation on the limits that IT can ofer putting more burden on the Scientists for triage and quotas – business and scientific value
• New capabilities in organizations: hands on in data management tactical of data management not IT bur data engineering
• Citizen Science: privacy vs plants and microbes – no privacy issues
• Incentives need be changed for Data Citations in addition to Papers
• Curation Citations as Authorship citation
• Data sharing in Cancer: GEN3 – NCI Data Commons, Data Governance and Data Permission (Access) – NCI does work in data commons – much data outside this space
• EBI – in UK Sanger Institute has the infrastructure in one place
• Migrating Project based Data structure: that involves scientist decisions that should not be a quota (storage is full)  in the IT space
• Human to Human communications vs tools for data migration
• Which Organizations get the data curation and annotation well: Subject matter from day 1 – hard to teach vs data engineering skills; TEAM as a solving is critical in Biomedical space no incentives
• BBC – Meta tagging system is outstanding
• NCAST TRANSLATOR – across organizations
• Changing incentives – MORE organizations will do that task better
• Common metadata across domains with predict uses of data in the Future – collaboration of CS to create in the science organization tagging like in BBC

TRACK 16: OPEN ACCESS AND COLLABORATIONSTRACK 15: CANCER INFORMATICSTRACK 13: GENOME INFORMATICS

Session Wrap-Up Panel Discussion

• 

  Chris Anderson

  Clinical OMICs

  Editor in Chief

Ian Fore

NIH NCI

Sr Biomedical Informatics Program Mgr

• NCI – Cancer Data Commons – concierge services to organization on data services

Ravi Madduri – CVD large cohort

Univ of Chicago

Scientist

 

• 

  Lara Mangravite

  Sage Bionetworks

  President

• 

  Kees Van Bochove

  The Hyve

  Founder & Owner

11:10 AM – 11:30 AM EDT on Thursday, October 8

 

BREAKOUT: Driving Scientific Discovery with Data / Digitization

• 

  Timothy Gardner

  Riffyn Inc

  CEO

11:35 AM – 12:00 PM EDT on Thursday, October 8

 

PLENARY KEYNOTE – 12:00 PM – 1:25 PM EDT on Thursday, October 8

Robert Green

Brigham & Womens Hospital

Co-founder of Genome Medicine

Prof & Dir G2P Research

• Combining data to rapidly analyze COVID-19 Patients –
• identify BIOMARKERS for vulnerability
• Preventive Genomics – Angelina Jolly’s musectomy as a preventive clinical condition
• Patients access to own genomics data
• Population screening – to predict risks
• Genetic Testing to Consumer: Preventive Genomics: conflated genotyping/sequencing and labs/care providers
• Genetic Testing to Consumer: COST & Benefits – UNCLEAR

1. diagnosis of unsuspected genetic disease
2. stratification for surveillance
3. which pieces of the puzzle need to be brought to bear in patient care
4. Categories and Reporting criteria: Gene-Disease validity vs Variant Pathogenicity –>> Clinic
5. MedSeq Project: 10MM randomized study – all genome info shared with Patient, other arm only selective genome data shared with patient: 100 patients 20% carry monogenic condition: Polygenic risk scores:
6. CAD – high Cholesterol biomarker, A-FIb, DM2, 52% Women 48% Men
7. No high risk error by PCP discussing and disclosing the results of the sequence
8. Filtering the results: Indication -based testing vs Screening
9. BabySeq Project: INFANTS sequencing to prevent disease: 11% carry a mutation in a monogenic gene for a monogenic condition -like abnormal narrowed aorta
10. MDR – Monogenic Disease Risk
11. MilSeq Project: US Air Force – Military active duty
12. 5,8,10 – are all Polygenic studies
13. Polygenic Risk Scores – High risk
14. Classification need to be repeated every few years (2 years – re-sequence) due to changes in health and to efficiencies in new discovery in curated data which is improving as on-going

• Risk benefit – UTILITY – Partners Biobank Return of Genomic Results
• No interest on knowing by the Public NCCN criteria on chart review 20%
• Brigham Preventive Genomics via telemedicine – First in the country
• APC mutation after colonoscopy – obstruction diagnosed
  www.genomes2people.org 
• @robertgreen

 

Juergen Klenk

Deloitte Consulting LLP

Principal

• Bradykinin hypothesis for COVID-19
• liberate the data: People , Data Risk

 

Natalija Jovanovic

Sanofi

Chief Digital Officer

• AI in Pharma
• Vaccine preventable diseases – produce 1Billion vaccines a year

1. reduction of incidence: Pertusis – 92% eradication

• manage risk profile
• Science mechanism translatable to machines

1. high automated ingestible data for AI
2. Digital is about people: Good data Good algorithms Good GUI

Vivien Bonazzi

Deloitte Consulting LLP

Managing Dir & Chief Biomedical Data Scientist

12:00 PM – 1:25 PM EDT on Thursday, October 8
Add to Calendar

12:00 Organizer’s Remarks

Cindy Crowninshield, RDN, LDN, Executive Event Director, Cambridge Healthtech Institute

12:05 Keynote Introduction

Juergen A. Klenk, PhD, Principal, Deloitte Consulting LLP

12:15 Toward Preventive Genomics: Lessons from MedSeq and BabySeq

Robert Green, MD, MPH, Professor of Medicine (Genetics) and Director, G2P Research Program/Preventive Genomics Clinic, Brigham & Women’s Hospital, Broad Institute, and Harvard Medical School

12:40 AI in Pharma: Where We Are Today and How We Will Succeed in the Future

Natalija Jovanovic, PhD, Chief Digital Officer, Sanofi Pasteur

1:05 LIVE Q&A: Session Wrap-Up Panel Discussion

PANEL MODERATORS:

Juergen A. Klenk, PhD, Principal, Deloitte Consulting LLP

Vivien R. Bonazzi, PhD, Managing Director & Chief Biomedical Data Scientist, Deloitte Consulting LLP

• PLENARY

Below are included sessions that are NOT included above. I covered ONLY the above sessions.

Session Availability

1. PLENARY KEYNOTE PRESENTATION

10:15 am ET – NIH’s Strategic Vision for Data Science Susan K. Gregurick, PhD, Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS), National Institutes of Health Rebecca Baker, PhD, Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director, National Institutes of Health

2. WORKSHOPS

11:55 am ET – W1: Data Management for Biologics: Registration and Beyond Monica Wang, PhD, Principal Technology Lead, Scientific Informatics, Takeda Sebastian Schlicker, Head, Biologics Business Operations, Genedata AG 11:55 am ET – W2: A Crash Course in AI: 0-60 in Three Peter V. Henstock, PhD, Machine Learning & AI Lead, Software Engineering & Statistics & Visualization, Pfizer Inc. 11:55 am ET – W3: Data Science Driving Better Informed Decisions Meghan Raman, Director, R&D Data Lake & Analytics, Bristol Myers Squibb Co. Nigel Greene, PhD, Director & Head Data Science & Artificial Intelligence, Drug Safety & Metabolism, AstraZeneca Pharmaceuticals 2:15 pm ET – W4: Digital Biomarkers and Wearables in Pharma R&D and Clinical Trials Danielle Bradnan, MS, Research Associate, Digital Health and Wellness, Lux Research Graham Jones, PhD, Director, Innovation, Technical Research and Development, Novartis Ariel Dowling, PhD, Director of Digital Strategy, Data Sciences Institute, Research and Development, Takeda Pharmaceuticals 2:15 pm ET – W5: AI-Celerating R&D: Foundational Approaches to How Emerging Technologies Can Create Value Brian Martin, Head of AI, R&D Information Research, Senior Principal Data Scientist, AbbVie 2:15 pm ET – W6: Dealing with Instrument Data at Scale: Challenges and Solutions Rachana Ananthakrishnan, Executive Director, Globus, University of Chicago Michael A. Cianfrocco, PhD, Assistant Professor, Department of Biological Chemistry and Research Assistant Professor, Life Sciences Institute, University of Michigan Brigitte E. Raumann, Product Manager, Globus, University of Chicago

3. Connect with peers from across the industry during these dedicated networking times.

9:25 am ET – Virtual Exhibit Hall Open 1:00 pm ET – Speed Networking Looking to meet fellow attendees and have meaningful conversations – just as you would at an in- person event? This is the perfect way to achieve just that. Get to know your fellow attendees by joining this interactive speed networking event. To participate, each attendee will be paired at random with another fellow attendee and given a chance to interact for 7 minutes in a private zoom room. Once the 7 minutes are up, you will move on to meet with another selected attendee. Maximize your networking at the meeting and join in. 2:00 pm ET – Stretch Break Take a minute to revitalize and join our friends from VOS Fitness for a stretch break. The professional trainer from VOS will bring you through some easy moves that will help with screen fatigue and ease your muscles after a long day of sitting at the computer. All moves can be done right at your desk and is appropriate for all fitness levels.

4. Game On!

Earn points by completing the activities listed on our Game tab. Some activities will only award points once, but others will award you every time you do it – so the more involved you are in the virtual event, the more points you will earn! You can start earning points one week before the event – so get ready to start sending meeting invitations, exploring our virtual expo and planning your schedule. Attendees in the top 5% of points earned when the game closes at the end of the conference will be eligible to win a gift card worth $200 USD!

5. Take part in 1-on-1 networking with an easy-to-navigate profile search and scheduling platform.

Check out your recommended connections flagged as “Want to Meet” in the People Tab. These connections were chosen based on your similar roles, companies and conference program interests. Take a moment to add relevant interest tags to your profile. Then search and connect with participants who have the same interests. Engage with technology leaders in their booths and view relevant videos and demos. Take part in live Q&A with speakers and participants following each educational session. Create and join in ad hoc group discussions throughout the event. Watch Our Quick Tutorial on how to Maximize Networking Opportunities: CII’s Virtual Event Platform – Networking

10:00 AM – 11:25 AM EDT on Tuesday, October 6
Add to Calendar

SPONSORED BY:

10:00 Welcome Remarks

Cindy Crowninshield, RDN, LDN, Executive Event Director, Cambridge Healthtech Institute

10:05 Keynote Introduction

Scott Parker, Director of Product Marketing, Marketing, Sinequa

10:15 PLENARY KEYNOTE PRESENTATION: NIH’s Strategic Vision for Data Science

Susan K. Gregurick, PhD, Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS), National Institutes of Health

Rebecca Baker, PhD, Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director, National Institutes of Health

11:05 LIVE Q&A: Session Wrap-Up Panel Discussion

PANEL MODERATOR:

Ari E Berman, PhD, CEO, BioTeam Inc

• PLENARY

Session Availability

• ON DEMAND
• LIVE

• OPEN TO ALL

Wednesday, October 7

9:00 AM EDT

• TRACK 7: AI FOR DRUG DISCOVERY

  The Emergence of the AI-Augmented Drug Discoverer

  9:00 AM – 9:20 AM EDT
  PRESENTATIONON DEMANDRECORDEDSESSION PASS
  

  Mark Davies

  BenevolentAI

9:20 AM EDT

• TRACK 7: AI FOR DRUG DISCOVERY

  Generative Chemistry and Generative Biology for AI-Powered Drug Discovery

  9:20 AM – 9:40 AM EDT
  PRESENTATIONON DEMANDRECORDEDSESSION PASS
  

  Alex Zhavoronkov

  Insilico Medicine

9:40 AM EDT

• TRACK 7: AI FOR DRUG DISCOVERY

  Talk Title to be Announced

  9:40 AM – 11:00 AM EDT
  PRESENTATIONON DEMANDRECORDEDSESSION PASS
  

  Grace Wenjia You

  EMD Serono

11:00 AM EDT

• TRACK 7: AI FOR DRUG DISCOVERY

  Coupling AI and Network Biology to Generate Insights for Disease Understanding and Target ID

  11:00 AM – 11:30 AM EDT

  
  PRESENTATIONON DEMANDRECORDEDSESSION PASS
  

  Alexander Ivliev

  Clarivate

11:30 AM EDT

• TRACK 7: AI FOR DRUG DISCOVERY

  Session Wrap-Up Panel Discussion

  11:30 AM – 11:50 AM EDT
  PANELON DEMANDLIVESESSION PASS

 

@@@@@

OLD Material

http://www.giiconference.com/chi909998/

Welcome to Bio-IT World 2020

In the spirit of open collaboration, the world’s premier bio-IT conference will bring together the community to focus on how we are using technologies and analytic approaches to solve problems, accelerate science, and drive the future of precision medicine. With a focus on AI, data science and other “data-driven” technologies that are advancing biomedical research, drug discovery and healthcare, the Bio-IT World Conference & Expo ’20 will bring together more than 3,000 participants to the Seaport World Trade Center in Boston from October 6-8, 2020.

The participants will have the chance to meet and share research/ideas with leading life sciences, pharmaceutical, clinical, healthcare, informatics and technology experts.

BROCHURE

http://www.giiconference.com/chi909998/catalog.pdf?20200122

2020 CONFERENCE PROGRAMS VIEW

TRACK 1 Data Storage and Transport VIEW

TRACK 2 Data and Metadata Management VIEW

TRACK 3 Data Science and Analytics Technologies VIEW

TRACK 4 Software Applications and Services VIEW

TRACK 5 Data Security and Compliance VIEW

TRACK 6 Cloud Computing VIEW

TRACK 7 AI for Drug Discovery VIEW

TRACK 8 Emerging AI Technologies VIEW

TRACK 9 AI: Business Value Outcomes VIEW

TRACK 10 Data Visualization Tools VIEW

TRACK 11 Bioinformatics VIEW

TRACK 12 Pharmaceutical R&D Informatics VIEW

TRACK 13 Genome Informatics VIEW

TRACK 14 Clinical Research and Translational Informatics VIEW

TRACK 15 Cancer Informatics VIEW

TRACK 16 Open Access and Collaborations

 

2020 Plenary Keynote Speakers

Rebecca Baker, PhD

Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director, National Institutes of Health

Vivien Bonazzi, PhD

Chief Biomedical Data Scientist, Managing Director, Deloitte

Tim Cutts, PhD

Head, Scientific Computing, Wellcome Trust Sanger Institute

Chris Dagdigian

Co-Founder and Senior Director, Infrastructure, BioTeam, Inc

Kevin Davies, PhD

Executive Editor, The CRISPR Journal, Mary Ann Liebert, Inc.

Kjiersten Fagnan, PhD

Chief Informatics Officer, Data Science and Informatics Leader, DOE Joint Genome Institute, Lawrence Berkeley National Laboratory

Robert Green, MD, MPH

Professor of Medicine (Genetics) and Director, G2P Research Program/Preventive Genomics Clinic, Brigham & Women’s Hospital, Broad Institute, and Harvard Medical School

Susan K. Gregurick, PhD

Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS), National Institutes of Health

Natalija Jovanovic, PhD

Chief Digital Officer, Sanofi Pasteur

Pietro Michelucci, PhD

Director, Human Computation Institute

Matthew Trunnell

Vice President and Chief Data Officer, Fred Hutchinson Cancer Research Center

3,200+

Industry
Professionals

160+

Sponsors &
Exhibitors

250+

Scientific
Presentations

16

Diverse
Conference Tracks

Read Full Post »

Structure-guided Drug Discovery: (1) The Coronavirus 3CL hydrolase (Mpro) enzyme (main protease) essential for proteolytic maturation of the virus and (2) viral protease, the RNA polymerase, the viral spike protein, a viral RNA as promising two targets for discovery of cleavage inhibitors of the viral spike polyprotein preventing the Coronavirus Virion the spread of infection

Posted in Antibody Responses Predict Antigen Exposure, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, COVID-19, Immunodiagnostics, Immunology, Innovation in Immunology Diagnostics, MHC Repertoires for Antigen Prediction, Population Health Management, Population Health Management, Genetics & Pharmaceutical, Viral diseases, Virology - Vector-borne DIsease, tagged BioIT: BioInformatics, Biological Engineering, Biological Networks, Biomarkers & Medical Diagnostics, Cancer Informatics, Clinical & Translational, clinical genomics, Commercialization, COVID-19, Gene Regulation and Evolution, Genetics & Pharmaceutical, Immunotherapy, Innovation in Immunology Diagnostics, Innovations, Intellectual property, Investment in Technological Breakthrough, NGS, Pharmaceutical R&D Informatics, Population Health Management, Proteomics, SARS-CoV, SARS-CoV-2, Universal Immune Cell Therapies (uICT), Virus Infective Acute Respiratory Syndrome: SARS-CoV | Tagged COVID-19 on March 12, 2020| 1 Comment »

Structure-guided Drug Discovery: (1) The Coronavirus 3CL hydrolase (Mpro) enzyme (main protease) essential for proteolytic maturation of the virus and (2) viral protease, the RNA polymerase, the viral spike protein, a viral RNA as promising two targets for discovery of cleavage inhibitors of the viral spike polyprotein preventing the Coronavirus Virion the spread of infection

 

Curators and Reporters: Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN

 

Therapeutical options to coronavirus (2019-nCoV) include consideration of the following:

(a) Monoclonal and polyclonal antibodies

(b)  Vaccines

(c)  Small molecule treatments (e.g., chloroquinolone and derivatives), including compounds already approved for other indications 

(d)  Immuno-therapies derived from human or other sources

 

 

Structure of the nCoV trimeric spike

The World Health Organization has declared the outbreak of a novel coronavirus (2019-nCoV) to be a public health emergency of international concern. The virus binds to host cells through its trimeric spike glycoprotein, making this protein a key target for potential therapies and diagnostics. Wrapp et al. determined a 3.5-angstrom-resolution structure of the 2019-nCoV trimeric spike protein by cryo–electron microscopy. Using biophysical assays, the authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor. They also tested three antibodies known to bind to the SARS-CoV spike protein but did not detect binding to the 2019-nCoV spike protein. These studies provide valuable information to guide the development of medical counter-measures for 2019-nCoV. [Bold Face Added by ALA]

Science, this issue p. 1260

Abstract

The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo–electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.

SOURCE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

1. Daniel Wrapp¹,*,
2. Nianshuang Wang¹,*,
3. Kizzmekia S. Corbett²,
4. Jory A. Goldsmith¹,
5. Ching-Lin Hsieh¹,
6. Olubukola Abiona²,
7. Barney S. Graham²,
8. Jason S. McLellan¹,†

1. Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
2. 
   
   ²Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

1. ↵†Corresponding author. Email: jmclellan@austin.utexas.edu

1. ↵* These authors contributed equally to this work.

Science  13 Mar 2020:
Vol. 367, Issue 6483, pp. 1260-1263
DOI: 10.1126/science.abb2507

 

02/04/2020

New Coronavirus Protease Structure Available

PDB data provide a starting point for structure-guided drug discovery

A high-resolution crystal structure of COVID-19 (2019-nCoV) coronavirus 3CL hydrolase (Mpro) has been determined by Zihe Rao and Haitao Yang’s research team at ShanghaiTech University. Rapid public release of this structure of the main protease of the virus (PDB 6lu7) will enable research on this newly-recognized human pathogen.

Recent emergence of the COVID-19 coronavirus has resulted in a WHO-declared public health emergency of international concern. Research efforts around the world are working towards establishing a greater understanding of this particular virus and developing treatments and vaccines to prevent further spread.

https://doi.org/10.2210/pdb6lu7/pdb

While PDB entry 6lu7 is currently the only public-domain 3D structure from this specific coronavirus, the PDB contains structures of the corresponding enzyme from other coronaviruses. The 2003 outbreak of the closely-related Severe Acute Respiratory Syndrome-related coronavirus (SARS) led to the first 3D structures, and today there are more than 200 PDB structures of SARS proteins. Structural information from these related proteins could be vital in furthering our understanding of coronaviruses and in discovery and development of new treatments and vaccines to contain the current outbreak.

The coronavirus 3CL hydrolase (Mpro) enzyme, also known as the main protease, is essential for proteolytic maturation of the virus. It is thought to be a promising target for discovery of small-molecule drugs that would inhibit cleavage of the viral polyprotein and prevent spread of the infection.

Comparison of the protein sequence of the COVID-19 coronavirus 3CL hydrolase (Mpro) against the PDB archive identified 95 PDB proteins with at least 90% sequence identity. Furthermore, these related protein structures contain approximately 30 distinct small molecule inhibitors, which could guide discovery of new drugs. Of particular significance for drug discovery is the very high amino acid sequence identity (96%) between the COVID-19 coronavirus 3CL hydrolase (Mpro) and the SARS virus main protease (PDB 1q2w). Summary data about these closely-related PDB structures are available (CSV) to help researchers more easily find this information. In addition, the PDB houses 3D structure data for more than 20 unique SARS proteins represented in more than 200 PDB structures, including a second viral protease, the RNA polymerase, the viral spike protein, a viral RNA, and other proteins (CSV).

Public release of the COVID-19 coronavirus 3CL hydrolase (Mpro), at a time when this information can prove most vital and valuable, highlights the importance of open and timely availability of scientific data. The wwPDB strives to ensure that 3D biological structure data remain freely accessible for all, while maintaining as comprehensive and accurate an archive as possible. We hope that this new structure, and those from related viruses, will help researchers and clinicians address the COVID-19 coronavirus global public health emergency.

Update: Released COVID-19-related PDB structures include

• PDB structure 6lu7 (X. Liu, B. Zhang, Z. Jin, H. Yang, Z. Rao Crystal structure of COVID-19 main protease in complex with an inhibitor N3 doi: 10.2210/pdb6lu7/pdb) Released 2020-02-05
• PDB structure 6vsb (D. Wrapp, N. Wang, K.S. Corbett, J.A. Goldsmith, C.-L. Hsieh, O. Abiona, B.S. Graham, J.S. McLellan (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Science doi: 10.1126/science.abb2507) Released 2020-02-26
• PDB structure 6lxt (Y. Zhu, F. Sun Structure of post fusion core of 2019-nCoV S2 subunit doi: 10.2210/pdb6lxt/pdb) Released 2020-02-26
• PDB structure 6lvn (Y. Zhu, F. Sun Structure of the 2019-nCoV HR2 Domain doi: 10.2210/pdb6lvn/pdb) Released 2020-02-26
• PDB structure 6vw1
  J. Shang, G. Ye, K. Shi, Y.S. Wan, H. Aihara, F. Li Structural basis for receptor recognition by the novel coronavirus from Wuhan doi: 10.2210/pdb6vw1/pdb
  Released 2020-03-04
• PDB structure 6vww
  Y. Kim, R. Jedrzejczak, N. Maltseva, M. Endres, A. Godzik, K. Michalska, A. Joachimiak, Center for Structural Genomics of Infectious Diseases Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 doi: 10.2210/pdb6vww/pdb
  Released 2020-03-04
• PDB structure 6y2e
  L. Zhang, X. Sun, R. Hilgenfeld Crystal structure of the free enzyme of the SARS-CoV-2 (2019-nCoV) main protease doi: 10.2210/pdb6y2e/pdb
  Released 2020-03-04
• PDB structure 6y2f
  L. Zhang, X. Sun, R. Hilgenfeld Crystal structure (monoclinic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) doi: 10.2210/pdb6y2f/pdb
  Released 2020-03-04
• PDB structure 6y2g
  L. Zhang, X. Sun, R. Hilgenfeld Crystal structure (orthorhombic form) of the complex resulting from the reaction between SARS-CoV-2 (2019-nCoV) main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) doi: 10.2210/pdb6y2g/pdb
  Released 2020-03-04

SOURCE – 02/04/2020

https://www.wwpdb.org/news/news?year=2020&fbclid=IwAR0mFKQD7KX29hkJcnV0MxeAe_1themx7KuBDo8txaMiYHJ08JvNN0cisug#5e39e03fa5007a04a313edc3

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Kevin J. Clerkin , Justin A. Fried, Jayant Raikhelkar, Gabriel Sayer, Jan M. Griffin, Amirali Masoumi, Sneha S. Jain, Daniel Burkhoff, Deepa Kumaraiah, LeRoy Rabbani, Allan Schwartz

and

Nir Uriel

Originally published 21 Mar 2020 https://doi.org/10.1161/CIRCULATIONAHA.120.046941 Circulation. ;0:null

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic impacting nearly 170 countries/regions and more than 285,000 patients worldwide. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which invades cells through the angiotensin converting enzyme 2 (ACE2) receptor. Among those with COVID-19, there is a higher prevalence of cardiovascular disease and more than 7% of patients suffer myocardial injury from the infection (22% of the critically ill). Despite ACE2 serving as the portal for infection, the role of ACE inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, impacting donor selection, immunosuppression, and post-transplant management. Thankfully there are a number of promising therapies under active investigation to both treat and prevent COVID-19. Key Words: COVID-19; myocardial injury; pandemic; heart transplant

SOURCE

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.046941

ACE2

• Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA, Pantoliano MW (Apr 2004). “ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis”. The Journal of Biological Chemistry. 279 (17): 17996–8007. doi:10.1074/jbc.M311191200. PMID 14754895.

 

• Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM (Apr 2002). “ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors”. Canadian Journal of Physiology and Pharmacology. 80 (4): 346–53. doi:10.1139/y02-021. PMID 12025971.

 

•  Zhang, Haibo; Penninger, Josef M.; Li, Yimin; Zhong, Nanshan; Slutsky, Arthur S. (3 March 2020). “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target”. Intensive Care Medicine. Springer Science and Business Media LLC. doi:10.1007/s00134-020-05985-9. ISSN 0342-4642. PMID 32125455.

 

• ^ Gurwitz, David (2020). “Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics”. Drug Development Research. doi:10.1002/ddr.21656. PMID 32129518.

 

Angiotensin converting enzyme 2 (ACE2)

is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin[1-9]^[5] or the conversion of angiotensin II to angiotensin 1-7.^[6][7] ACE2 has direct effects on cardiac function^a and is expressed predominantly in vascular endothelial cells of the heart and the kidneys.^[8] ACE2 is not sensitive to the ACE inhibitor drugs used to treat hypertension.^[9]

ACE2 receptors have been shown to be the entry point into human cells for some coronaviruses, including the SARS virus.^[10] A number of studies have identified that the entry point is the same for SARS-CoV-2,^[11] the virus that causes COVID-19.^{[12][13][14][15]}

Some have suggested that a decrease in ACE2 could be protective against Covid-19 disease^[16], but others have suggested the opposite, that Angiotensin II receptor blocker drugs could be protective against Covid-19 disease via increasing ACE2, and that these hypotheses need to be tested by datamining of clinical patient records.^[17]

REFERENCES

https://en.wikipedia.org/wiki/Angiotensin-converting_enzyme_2

 

FOLDING@HOME TAKES UP THE FIGHT AGAINST COVID-19 / 2019-NCOV

February 27, 2020

by Greg Bowman

We need your help! Folding@home is joining researchers around the world working to better understand the 2019 Coronavirus (2019-nCoV) to accelerate the open science effort to develop new life-saving therapies. By downloading Folding@Home, you can donate your unused computational resources to the Folding@home Consortium, where researchers working to advance our understanding of the structures of potential drug targets for 2019-nCoV that could aid in the design of new therapies. The data you help us generate will be quickly and openly disseminated as part of an open science collaboration of multiple laboratories around the world, giving researchers new tools that may unlock new opportunities for developing lifesaving drugs.

2019-nCoV is a close cousin to SARS coronavirus (SARS-CoV), and acts in a similar way. For both coronaviruses, the first step of infection occurs in the lungs, when a protein on the surface  of the virus binds to a receptor protein on a lung cell. This viral protein is called the spike protein, depicted in red in the image below, and the receptor is known as ACE2. A therapeutic antibody is a type of protein that can block the viral protein from binding to its receptor, therefore preventing the virus from infecting the lung cell. A therapeutic antibody has already been developed for SARS-CoV, but to develop therapeutic antibodies or small molecules for 2019-nCoV, scientists need to better understand the structure of the viral spike protein and how it binds to the human ACE2 receptor required for viral entry into human cells.

Proteins are not stagnant—they wiggle and fold and unfold to take on numerous shapes.  We need to study not only one shape of the viral spike protein, but all the ways the protein wiggles and folds into alternative shapes in order to best understand how it interacts with the ACE2 receptor, so that an antibody can be designed. Low-resolution structures of the SARS-CoV spike protein exist and we know the mutations that differ between SARS-CoV and 2019-nCoV.  Given this information, we are uniquely positioned to help model the structure of the 2019-nCoV spike protein and identify sites that can be targeted by a therapeutic antibody. We can build computational models that accomplish this goal, but it takes a lot of computing power.

This is where you come in! With many computers working towards the same goal, we aim to help develop a therapeutic remedy as quickly as possible. By downloading Folding@home here [LINK] and selecting to contribute to “Any Disease”, you can help provide us with the computational power required to tackle this problem. One protein from 2019-nCoV, a protease encoded by the viral RNA, has already been crystallized. Although the 2019-nCoV spike protein of interest has not yet been resolved bound to ACE2, our objective is to use the homologous structure of the SARS-CoV spike protein to identify therapeutic antibody targets.

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. A novel coronavirus virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. Image and Caption Credit: Alissa Eckert, MS; Dan Higgins, MAM available at https://phil.cdc.gov/Details.aspx?pid=23311

Structures of the closely related SARS-CoV spike protein bound by therapeutic antibodies may help rapidly design better therapies. The three monomers of the SARS-CoV spike protein are shown in different shades of red; the antibody is depicted in green. [PDB: 6NB7 https://www.rcsb.org/structure/6nb7]

(post authored by Ariana Brenner Clerkin)

References:

PDB 6lu7 structure summary ‹ Protein Data Bank in Europe (PDBe) ‹ EMBL-EBI https://www.ebi.ac.uk/pdbe/entry/pdb/6lu7 (accessed Feb 5, 2020).

Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; et al. Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-Specific Human Monoclonal Antibody; preprint; Microbiology, 2020. https://doi.org/10.1101/2020.01.28.923011.

Walls, A. C.; Xiong, X.; Park, Y. J.; Tortorici, M. A.; Snijder, J.; Quispe, J.; Cameroni, E.; Gopal, R.; Dai, M.; Lanzavecchia, A.; et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 2019, 176, 1026-1039.e15. https://doi.org/10.2210/pdb6nb7/pdb.

SOURCE

https://foldingathome.org/2020/02/27/foldinghome-takes-up-the-fight-against-covid-19-2019-ncov/

UPDATED 3/13/2020

I am reposting the following Science blog post from Derrick Lowe as is and ask people go browse through the comments on his Science blog In the Pipeline because, as Dr. Lowe states that in this current crisis it is important to disseminate good information as quickly as possible so wanted the readers here to have the ability to read his great posting on this matter of Covid-19.  Also i would like to direct readers to the journal Science opinion letter concerning how important it is to rebuild the trust in good science and the scientific process.  The full link for the following In the Pipeline post is: https://blogs.sciencemag.org/pipeline/archives/2020/03/06/covid-19-small-molecule-therapies-reviewed

A Summary of current potential repurposed therapeutics for COVID-19 Infection from In The Pipeline: A Science blog from Derick Lowe

Covid-19 Small Molecule Therapies Reviewed

By Derek Lowe 6 March, 2020

Let’s take inventory on the therapies that are being developed for the coronavirus epidemic. Here is a very thorough list of at Biocentury, and I should note that (like Stat and several other organizations) they’re making all their Covid-19 content free to all readers during this crisis. I’d like to zoom in today on the potential small-molecule therapies, since some of these have the most immediate prospects for use in the real world.

The ones at the front of the line are repurposed drugs that are already approved for human use, for a lot of obvious reasons. The Biocentury list doesn’t cover these, but here’s an article at Nature Biotechnology that goes into detail. Clinical trials are a huge time sink – they sort of have to be, in most cases, if they’re going to be any good – and if you’ve already done all that stuff it’s a huge leg up, even if the drug itself is not exactly a perfect fit for the disease. So what do we have? The compound that is most advanced is probably remdesivir from Gilead, at right. This has been in development for a few years as an RNA virus therapy – it was originally developed for Ebola, and has been tried out against a whole list of single-strand RNA viruses. That includes the related coronaviruses SARS and MERS, so Covid-19 was an obvious fit.

The compound is a prodrug – that phosphoramide gets cleaved off completely, leaving the active 5-OH compound GS-44-1524. It mechanism of action is to get incorporated into viral RNA, since it’s taken up by RNA polymerase and it largely seems to evade proofreading. This causes RNA termination trouble later on, since that alpha-nitrile C-nucleoside is not exactly what the virus is expecting in its genome at that point, and thus viral replication is inhibited.

There are five clinical trials underway (here’s an overview at Biocentury). The NIH has an adaptive-design Phase II trial that has already started in Nebraska, with doses to be changed according to Bayesian readouts along the way. There are two Phase III trials underway at China-Japan Friendship Hospital in Hubei, double-blinded and placebo-controlled (since placebo is, as far as drug therapy goes, the current standard of care). And Gilead themselves are starting two open-label trials, one with no control arm and one with an (unblinded) standard-of-care comparison arm. Those might read out first, depending on when they get off the ground, but will be only rough readouts due to the fast-and-loose trial design. The two Hubei trials and the NIH one will add some rigor to the process, but I’m not sure when they’re going to report. My personal opinion is that I like the chances of this drug more than anything else on this list, but it’s still unlikely to be a game-changer.

There’s an RNA polymerase inhibitor (favipiravir) from Toyama, at right, that’s in a trial in China. It’s a thought – a broad-spectrum agent of this sort would be the sort of thing to try. But unfortunately, from what I can see, it has already turned up as ineffective in in vitro tests. The human trial that’s underway is honestly the sort of thing that would only happen under circumstances like the present: a developing epidemic with a new pathogen and no real standard of care. I hold out little hope for this one, but given that there’s nothing else at present, it probably should be tried. As you’ll see, this is far from the only situation like this.

One of the screens of known drugs in China that also flagged remdesivir noted that the old antimalarial drug chloroquine seemed to be effective in vitro. It had been reported some years back as a possible antiviral, working through more than one mechanism, probably both at viral entry and intracellularly thereafter. That part shouldn’t be surprising – chloroquine’s actual mode(s) of action against malaria parasites are still not completely worked out, either, and some of what people thought they knew about it has turned out to be wrong. There are several trials underway with it at Chinese facilities, some in combination with other agents like remdesivir. Chloroquine has of course been taken for many decades as an antimalarial, but it has a number of liabilities, including seizures, hearing damage, retinopathy and sudden effects on blood glucose. So it’s going to be important to establish just how effective it is and what doses will be needed. Just as with vaccine candidates, it’s possible to do more harm with a rushed treatment than the disease is doing itself

There are several other known antiviral drugs are being tried in China, but I don’t have too much hope for those, either. The neuraminidase inhibitors such as oseltamivir (better known as Tamiflu) were tried against SARS and were ineffective; there is no reason to expect anything versus Covid-19 although these drugs are a component of some drug cocktail trials. The HIV protease therapies such as darunavir and the combination therapy Kaletra are in trials, but that’s also a rather desperate long shot, since there’s no particular reason to think that they will have any such protease inhibition against what this new virus has to offer (and indeed, such agents weren’t much help against SARS in the end, either). The classic interferon/ribavirin combination seems to have had some activity against SARS and MERS, and is in two trials from what I can see. That’s not an awful idea by any means, but it’s not a great one, either: if your viral disease has interferon/ribavirin as a front line therapy, it generally means that there’s nothing really good available. No, unless we get really lucky none of these ideas are going to slow the disease down much.

There are a few other repurposed-protease-inhibitors ideas out there, such as this one. (Edit: I had seen this paper but couldn’t track it down, so thanks to those who sent it along). This paper suggests that the TMPRSS2 protease is important for viral entry on the human-cell-side of the process, a pathway that has been noted for other coronaviruses. And it points out that there is a an approved inhibitor (in Japan) for this enzyme (camostat), so that would definitely seem to be worth a trial, probably in combination with remdesivir.

That’s about it for the existing small molecules, from what I can see. What about new ones? Don’t hold your breath, is all I can say. A drug discovery program from scratch against a new pathogen is, as many readers here well know, not a trivial exercise. As this Bloomberg article details, many such efforts in the past (small molecules and vaccines alike) have come to grief because by the time they had anything to deliver the epidemic itself had passed. Indeed, Gilead’s remdesivir had already been dropped as a potential Ebola therapy.

You will either need to have a target in mind up front or go phenotypic. For the former, what you’d see are better characterizations of the viral protease and more extensive screens against it. Two other big target areas are viral entry (which involves the “spike” proteins on the virus surface and the ACE2 protein on human cells) and viral replication. To the former, it’s worth quickly noting that ACE2 is so much unlike the more familiar ACE protein that none of the cardiovascular ACE inhibitors do anything to it at all. And targeting the latter mechanisms is how remdesivir was developed as a possible Ebola agent, but as you can see, that took time, too. Phenotypic screens are perfectly reasonable against viral pathogens as well, but you’ll need to put time and effort into that assay up front, just as with any phenotypic effort, because as anyone who does that sort of work will tell you, a bad phenotypic screen is a complete waste of everyone’s time.

One of the key steps for either route is identifying an animal model. While animal models of infectious disease can be extremely well translated to human therapy, that doesn’t happen by accident: you need to choose the right animal. Viruses in general (and coronaviruses are no exception) vary widely in their effects in different species, and not just across the gaps of bird/reptile/human and the like. No, you’ll run into things where even the usual set of small mammals are acting differently from each other, with some of them not even getting sick at all. This current virus may well have gone through a couple of other mammalian species before landing on us, but you’ll note that dogs (to pick one) don’t seem to have any problem with it.

All this means that any new-target new-chemical-matter effort against Covid-19 (or any new pathogen) is going to take years, and there is just no way around that. Update: see here for just such an effort to start finding fragment hits for the viral protease. This puts small molecules in a very bimodal distribution: you have the existing drugs that might be repurposed, and are presumably available right now. Nothing else is! At the other end, for completely new therapies you have the usual prospects of drug discovery: years from now, lots of money, low success rate, good luck to all of us. The gap between these two could in theory be filled by vaccines and antibody therapies (if everything goes really, really well) but those are very much their own area and will be dealt with in a separate post.

Either way, the odds are that we (and I mean “we as a species” here) are going to be fighting this epidemic without any particularly amazing pharmacological weapons. Eventually we’ll have some, but I would advise people, pundits, and politicians not to get all excited about the prospects for some new therapies to come riding up over the hill to help us out. The odds of that happening in time to do anything about the current outbreak are very small. We will be going for months, years, with the therapeutic options we have right now. Look around you: what we have today is what we have to work with.

Other related articles published in this Open Access Online Scientific Journal include the following:

 

Group of Researchers @ University of California, Riverside, the University of Chicago, the U.S. Department of Energy’s Argonne National Laboratory, and Northwestern University solve COVID-19 Structure and Map Potential Therapeutics

Reporters: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/03/06/group-of-researchers-solve-covid-19-structure-and-map-potential-therapeutic/

Predicting the Protein Structure of Coronavirus: Inhibition of Nsp15 can slow viral replication and Cryo-EM – Spike protein structure (experimentally verified) vs AI-predicted protein structures (not experimentally verified) of DeepMind (Parent: Google) aka AlphaFold

Curators: Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/03/08/predicting-the-protein-structure-of-coronavirus-inhibition-of-nsp15-can-slow-viral-replication-and-cryo-em-spike-protein-structure-experimentally-verified-vs-ai-predicted-protein-structures-not/

 

Coronavirus facility opens at Rambam Hospital using new Israeli tech

https://www.jpost.com/Israel-News/Coronavirus-facility-opens-at-Rambam-Hospital-using-new-Israeli-tech-619681

 

Read Full Post »

Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Join 2,045 other followers

  Email Address:

  Follow

• Recent Posts

  • Two Site Map Proposals for LPBI’s New Web Site December 2, 2020
  • COVID-19 T-cell immune response map, immunoSEQ T-MAP COVID for research of T-cell response to SARS-CoV-2 infection November 20, 2020
  • Nanoparticles can turn off genes in bone marrow cells November 19, 2020
  • The complication of Pfizer’s Vaccine Distribution’s Plan November 19, 2020
  • Regeneron’s new antibody cocktail drug, REGN-COV2 November 18, 2020
  • McKinsey experts on COVID-19: Implications for business: Executive Briefing November 18, 2020
  • Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov November 18, 2020
  • re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers.  November 18, 2020
  • Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III November 16, 2020
  • First-ever living 3D-printed aneurysm November 15, 2020

• Archives

  Archives Select Month December 2020  (1) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (210)    3D Plotting Scaffolds  (42)    BioInks  (33)       Biopolymer Blend Open Porous  (17)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (62)       Cell Level  (8)       MicroEngineering Cell-Tissue & Systems  (21)       Tissue Engineering  (31)    Cardiovascular and Vascular Systems  (22)       Artificial Vascular Structures  (6)       Cardiovascular Tissue  (7)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (7)    MEMS  (14)       Bio-MEMS  (10)    Organ-on-a-Chip  (9)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (8) Academic Publishing  (210)    Key Opinion Leaders in eScientific Publishing – Interviews with  (6) Advanced Drug Manufacturing Technology  (87)    Antimalarial Preparation  (7)    Autologous Cell Therapy  (11)    Automated Cell Processing  (10) AI  (13)    AI in healthcare  (9)    AI in Medical-Imaging  (4) Allergy and Infectious Diseases  (10) Alzheimer’s Disease  (150)    Etiology  (72)    Medical Device Therapies for Altzheimer’s Disease  (13)    Pharmacotherapy and Cell Activity  (48) Anticancer Resistance  (26) Aortic Valve: TAVR  (3) Art Exhibits on the Human Condition  (1) Art Inspires Science  (3) Artificial Heart  (2) Artificial Intelligence – General  (110)    An executive’s guide to AI  (7)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (57)    Artificial Intelligence Applications in Health Care  (53)       Artificial Intelligence in CANCER  (14)       Artificial Intelligence in Health Care – Tools & Innovations  (33)    Artificial Intelligence in Medicine – Application for Diagnosis  (37)       Artificial intelligence applications for cardiology  (19)          AI-assisted Cardiac MRI  (8)       Artificial Intelligence in Psychiatry  (5)       Deep Learning in Pathology  (10)    Artificial Intelligence in Medicine – Applications in Therapeutics  (29)    Machine Learning  (3)       Natural Language Processing (NLP)  (3) Auditory and vision  (11) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (17)    Crohn’s disease  (4)    Tolerance-inducing Autoimmune Disease Therapeutics  (2)    Ulcerative Colitis  (3) Autophagosome  (2) Bacterial Resistance  (23) Behavior  (21) Behavioral Genetics  (18) Big Data  (61)    Intelligent Information Systems  (37) Bio Instrumentation in Experimental Life Sciences Research  (356)    Analytical Instruments Industry  (3)    Microfuidics  (6) Bio-Ethics  (8) BioBanking  (29) Biodegradable Drug-eluting Material  (7) Bioengineering & reverse engineering design  (40) BioIT: BioInformatics  (115) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (93)    Advanced Computing Platform  (9)       Blockchain Transactions System  (1)    Pancreatic adenocarcinoma classifier  (3)    Simulation Modeling in NGS  (1) Biological Engineering  (32) Biological Networks  (172) Biological Networks, Gene Regulation and Evolution  (455)    Virology  (3) Biomarkers & Medical Diagnostics  (550)    VOC – Volatile Organic Compounds as BioMarkers  (1) Biomedical Measurement Science  (166) BioSimilars  (107) BioTechnology – Venture Creation  (113)    Foundations for supporting Science and Education  (11)    Philanthropy to Academic Institution  (2) BioTechnology – Venture Creation, Venture Capital  (95)    Seeking Talent  (2) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (77) Brain Basis of Emotion  (4) Business Career Consideration  (1) Ca2+ triggered activation  (57) Calcium  (16) Calcium Signaling  (65) Calmodulin Kinase and Contraction  (32) Cancer – General  (159) Cancer and Current Therapeutics  (380)    interventional oncology  (38)       Breast Cancer – impalpable breast lesions  (17)       Prostate Cancer: Monitoring vs Treatment  (6) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,053)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (50)       Circulating Tumor Cells (CTC)  (14)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (11)             mRNA  (3)          MagSifter chip  (1)       KRAS Mutation  (3)       Li-fraumeni syndrome.  (2)       TP53 – Germline mutations  (3)    cancer metabolism  (15)    Funding Opportunities for Cancer Research  (9)    Genomic Expression  (134)    Glioblastoma  (5)    Hexokinase  (14)    Loss of function gene  (14)    Metabolic Immuno-Oncology  (11)    Metastasis Process  (6)    Methylation  (29)    Microbiome and Responses to Cancer Therapy  (5)    Monoclonal Immunotherapy  (26)    mtDNA  (12)    Oxidative phosphorylation  (54)    Pancreatic cancer  (9)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (10)    Warburg effect  (49) Cancer Informatics  (88) Cancer Prevention: Research & Programs  (123) Cancer Screening  (95) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (21)    Engineering Enhanced Cancer Vaccines  (3) Cardiac and Cardiovascular Surgical Procedures  (287)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (80)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (1)       TAVI vs Open Heart Surgery  (4)       Valve-in-Valve Procedure  (3)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (12)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (43)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (13)    Heart-Lung Transplant  (8)    Implantation  (1)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (19)    Mitral Valve: Repair and Replacement  (58)       TMVR – Transcatheter Mitral Valve Repair  (2)    PCI  (94)       Bioresorbable Vascular Scaffold (BVS)  (3)       Robotic-assisted percutaneous coronary intervention  (1)       Stent Retriever in endovascular thrombectomy  (1)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (57)       Abdominal Aorta  (19)       Carotid Artery  (15)       Thoracic Aorta  (15)    Pulmonary Valve Replacement and Repair  (1)    Renal Denervation  (20)    Replacement  (1)    Tricuspid Valve Repair  (5)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (1) Cardiovascular Pharmacogenomics  (168) Cargo  (3) Cell Biology  (298) Cell Biology, Signaling & Cell Circuits  (634)    Apoptosis  (11)    Autophagy-Modulating Proteins  (3)    “Antibody–enzyme conjugates”  (2)    Cell Processing System in Cell Therapy Process Development  (15)    Endoplasmic reticulum  (2)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (1)    Ubiquitin  (5) Cerebrovascular and Neurodegenerative Diseases  (107)    Stroke  (2) Chemical Biology and its relations to Metabolic Disease  (452)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (7) Chemical Genetics  (344) Child and Adolescent Psychiatry  (13) Childhood cancer  (12) Childhood malnutrition  (3) Circulating Progenitor Cells  (26)    Bone marrow derived cells  (16)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (230) Clinical Diagnostics  (206)    Mass automation of plasma proteins  (12) Clinical Genomics  (128) Coagulation Therapy and Internal Bleeding  (80) Cognition  (41) Commercialization  (19) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (459)    Computational Histopathology  (1)    Meta-analysis of transcriptome data  (8) Conference Coverage with Social Media  (449)    MassBio  (3) coronavirus  (8) COVID-19  (5) CRISPR/Cas9 & Gene Editing  (174)    CRISPR alternative for editing genes without cutting  (9)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (3)    CRISPR applied to Human Germ Line  (9)       Gene Editing Impact on Longevity  (4) CT  (18) Cytokines  (19) Cytoskeleton  (83) Developmental biology  (103) Diabetes Mellitus  (139)    Artificial Pancreas for Type1 Diabetes  (4)    Gestational diabetes  (2) Diagnostic Immunology  (53) Diagnostics and Lab Tests  (117)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (8) Digital HealthCare – biotech & internet joint ventures  (37) Disease Biology  (314) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (476) DNA repair  (56)    Apoptosis  (11)    Autophagy  (10)    Cell death pathways  (15)    Proteolysis  (6)    Proteosome  (5) Drug Delivery Platform Technology  (144)    Drug Carrier Design  (13)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (7) Drug Toxicity  (72) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (8) Embryology  (23) Empathy  (6) Endocrine Diseases  (57) Enzyme Induction  (41)    ion-transporting enzyme  (1)    K + -ATPase.  (1)    Na +  (1) Epigenetics and Environmental Factors  (22) Ethics and Leadership  (9) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (64) FDA Regulatory Affairs  (349)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (50)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fiction and medicine  (4) Frontiers in Cardiology and Cardiovascular Disorders  (813)    Acute Myocardial Infarction  (48)       Cardiogenic Shock  (3)    Anemia in CVD Patients  (6)    Cardio-Oncology  (3)    Cardiomyopathy  (51)    Cardiovascular Research  (161)       Myocardial metabolism, Myocardial ischemia, Myocardial adenine nucleotide metabolism  (43)       Pre-Clinical Animal Model Development  (22)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (19)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (98)       Ablation Procedure vs Drug Therapy  (1)       Arrhythmia Detection with Machine Learning Algorithms  (5)       Genomic Analysis of EKG Electrophysiology Genomics  (2)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (4)    Epigenetics and Cardiovascular Risks  (53)    Heart Failure (HF)  (32)       Acute coronary syndrome  (5)       congestive heart failure  (16)    Medical Devices R&D and Inventions  (199)       Assist Devices: LV  (2)       RV  (1)       Stents & Tools  (87)       Valves & Tools  (63)    Origins of Cardiovascular Disease  (400)       Atherogenic Processes & Pathology  (165)       Congenital Heart DIsease  (34)          Genetic Mutations in Congenital Heart DIsease  (4)       inflammation independent of lipid levels  (10)       Systemic Inflammatory Diseases as CVD Risk  (9)    Pharmacotherapy of Cardiovascular Disease  (328)       HTN  (155)       HTN in Youth  (7)       Resident-cell-based  (42)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (6)       endovascular thrombectomy  (2)    Vascular Diseases  (11) Future Pandemics Inform-graphics  (1) Gastroenterology  (36) Gene Regulation  (217) Gene Regulation and Evolution  (129) Genetics & Innovations in Treatment  (158) Genetics & Pharmaceutical  (189) Genome Biology  (917)    Exosomes  (21)    Gene Therapy & Gene Editing Development  (25)    mRNA Therapeutics  (11)    Mutagenesis  (22)    Single Cell Genomics  (19)    Single-cell sequencing  (13)    Variation in human protein-coding regions  (20) Genomic Endocrinology  (38) Genomic Testing: Methodology for Diagnosis  (407) Genomics Pharmacy  (36) Global Market of Medical Devices Technology  (1) Global Medical Publishers by Country  (1) Global Partnering & Biotech Investment  (43) GLP  (4) Glycobiology: Biopharmaceutical Production  (12) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (25) Health Care System by Country  (30)    Centers for Medicare & Medicaid Services  (5)    Health in Israel  (1)    United States  (14)       Hospital-based Medical Innovations  (5)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (368)    Women Health  (10)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (152)    and Bioethics  (9)    Biotechnology  (8)    Health Law Policy  (4) HealthCare IT  (124) Healthcare Reform  (103)    Accountable Care Organizations  (23)    Affordable Care Act  (28)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (23)    Healthcare costs and reimbursement  (51)    Indigent Nutrition  (13)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (19)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (13)    Uninsured and Underinsured  (18) Hematology  (96)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (26) Human Immune System in Health and in Disease  (232) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (20) Image Processing/Computing  (39) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (119)    mRNA platform in Drug DIscovery  (5) Immunodiagnostics  (121)    Cancer-Immune Interactions  (16)    CNS-Immune Interface  (3)    Neuronal Circuits  (4) Immunology  (97)    Adaptive Immune Response to Biomaterials and Tissue Repair  (8)    Antibody Responses Predict Antigen Exposure  (10)    Cytokine Receptor Structure  (6)    Human Antibody Response  (13)    Human Circulating Antibody Repertoire  (9)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (7)    Synthetic Immunology: Hacking Immune Cells  (12) Immunotherapy  (109)    CAR-T  (13)    combination immunotherapies.  (10)    Efficacy of Anti-Tumor T Cells  (8)    Engineering Better T Cells  (7)    Immune Engineering  (12)    Immune Modulatory  (11)    Integrin-targeted Combination Immunotherapy  (5)    Modulating Macrophages in Cancer Immunotherapy  (10)    NK Cell-Based Cancer Immunotherapy  (13)    Synergistic Innate and Adaptive Immunotherapy  (12) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (148)    Antibiotic resistance  (4)    Viral diseases  (27) Infectious Disease Immunodiagnostics  (45)    Virology – Vector-borne DIsease  (11) Inflammasome  (26)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (2) Innovation in Immunology Diagnostics  (101)    Universal Immune Cell Therapies (uICT)  (8) Innovations  (173)    R&D Expenditure  (2) Innovations in Neurophysiology & Neuropsychology  (129)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (5)    hNPCs  (1)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (72)    Disputes and Settlements  (8)    IP Valuation Models – Pricing Intangible Assets  (3)    Patent Law in Biotech  (11) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (102) International Global Work in Pharmaceutical  (187) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (279)    Albany Medical Center Prize in Medicine and Biomedical Research  (1)    Annual Breakthrough Prize  (2)    Awards in Cardiology and Cardiovascular Medicine  (3)    CEOs of Biotech Companies  (1)    Gerald D Aurbach Award for Outstanding Translational Research  (1)    Interviews with Key Opinion Leaders (KOLs)  (4)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (1)    Lemelson-MIT Prize  (1)    Life Sciences Breakthrough Prize  (2)    Mosteller Statistician of the Year Award  (1)    Mourning the Loss of a Scientific Leader  (2)    National Academy of Sciences AWARDS  (1)    Nobel Prize WInners  (14)    Noble Prize (Not Nobel Prize)  (1)    Paul Marks Prize for Cancer Research  (1)    Russ Prize recognizes bioengineering achievements worldwide  (1)    The Dan David Prize  (5)    Warren Alpert Foundation Prize Recipients  (3)    Wolf Prize  (1)    Wolf Prize in Medicine  (1)    women in science  (2) Investment in Technological Breakthrough  (55) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (8) IP Development by LPBI Group Team & Other Organizations  (5) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (12) Leadership, Power, Social Interlocking Connections  (11) Lipid metabolism  (108)    Fatty acids  (37)    Lipids  (37)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (10) Liposome  (3) Liver & Digestive Diseases Research  (116) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (102)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (5)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (16)    PhD  (1)    RN  (1) LPBI Management  (3) Massachusetts Academy of Sciences (MAS)    (1) Materials Science & Engineering  (31) Math  (12)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (190) Medical Devices R&D Investment  (233)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (13)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (49) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (147)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (2)    Invasive FFR for PCI  (2)    MRI  (14)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (4)    Ultra Sound  (7) Melatonin & Circadian Regulation  (7) Metabolism  (226)    Biochemical pathways  (135)       Enzymes and isoenzymes  (69)          Dehydrogenase  (14)          Kinase  (27)          Phosphatase  (8)          Phosphorylase  (21)          tyrosine decarboxylases  (2)    Inosine nucleotides  (8)    Leloir pathway  (6)    microbiome  (6)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (315) Methods  (36) Mg++  (10) Microbiologial genetics  (31) Microbiology  (58)    Virology  (10) Micronutrients  (15) Microvesicle  (6) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (1) Molecular Genetics & Pharmaceutical  (368)    Organoids  (3) Monoclonal antibody therapy  (7) Mutant Gene Expression  (38) Myocardial adenine nucleotide metabolism  (5) Myocardial Ischemia  (24) Myocardial Metabolism  (34) Na-K transport  (39) Na-K-ATPase  (26) Nanotechnology for Drug Delivery  (89) Nephrology  (45) Nephrology & Regenerative medicine  (8) Neurodegenerative Diseases  (78)    hNPCs  (3)    MS  (4) Neurohumoral Transmission  (64)    Ca2+ triggered activation  (18)    Calmodulin  (11)    Parkinson’s disease dyskinesia levodopa  (2)    PKC  (13)    Synaptic vesicle  (19) Neurological Diseases  (111) Neuroscience  (118) Next Generation Sequencing (NGS)  (18)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (135) Nuclear Medicine  (11) Nutrigenomics  (67) Nutrition  (192)    Nutritional Supplements: Atherogenesis, lipid metabolism  (47) Nutrition and Phytochemistry  (59)    Minerals in Medicine  (4)    Plant extract  (21) Nutrition Disorders  (29) Nutritional Supplements: Atherogenesis  (30) Obesity  (17) Oligonucleotide Therapeutics & Delivery  (5) Oncolytic virus & OncoViro-Therapy  (18)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (22) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (32) Patient Experience  (60)    Art therapy  (1)    Hospital reputation  (6)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (27)    Reputation of Interventionist  (4)    Support Staff  (11)    Supportive therapies  (5)       laughfter  (1)    Surgical Procedure  (7) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (1) Personal Health Applications: Tech Innovations serves HealhCare  (31) Personalized and Precision Medicine & Genomic Research  (698)    Longevity  (1)    Patient-centered Medicine  (28)       cell-based therapy  (6)       stem cell biology and patient-specific  (6)    Personalized Medicine Coalition  (5)    Precision Cancer Medicine  (12) Phagophore  (1) Pharmaceutical Analytics  (257)    Pharmacologic toxicities  (61) Pharmaceutical Discovery  (98)    Rapid automation of plasma protein pools  (16) Pharmaceutical Drug Discovery  (178)    Drug Development Process  (37)       Drug Discovery Chemistry  (18)    drug repurposing  (7) Pharmaceutical Industry Competitive Intelligence  (330)    Pharmacovigilance  (5)    Value-based Drug Pricing  (7) Pharmaceutical R&D Informatics  (40) Pharmaceutical R&D Investment  (296) Pharmacodynamics and Pharmacokinetics  (20) Pharmacogenomics  (154) Photography Collection  (1) Physics  (12) Placenta  (5) Population genetics  (25) Population Health Management  (174)    Evolution of Biology Through Culture  (11)    U.S. Employment-to-Population Ratio  (7) Population Health Management, Genetics & Pharmaceutical  (570)    COVID-19  (117)       Biomarkers: Inflammation  (28)       Cancer Researchers Fighting COVID-19  (12)       COVID-19 effects on Human Heart  (8)       COVID-19: Pandemic Surgery Guidance  (16)       Economic Impact of Coronavirus Pandemic  (39)       number of asymptomatic infections  (24)       Treatment Protocols for COVID-19  (46)    SARS-CoV-2  (99)       Coronavirus Gene Expression  (40)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (20)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (26)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (13)       Seasonality & Environmental Factors in Resurgence  (23)       Serology tests for coronavirus antibodies  (39)       T-cell response to SARS-CoV-2 infection  (1)       Vaccinology  (31)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (72) Population Health Management, Nutrition and Phytochemistry  (149) Preimplantation Genetic Diagnosis and Reproductive Genomics  (8) Protein-energy malnutrition  (11) Proteomics  (350)    Amino acids  (49)    Proteins  (127) Pulmonary diseases  (14)    Lung and pulmonology  (13) Pulmonary pathology  (6) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (28) Regenerative Biology and Medicine  (80) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (263) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (101) Reproductive Biology & Bio Instrumentation  (67) RNA Biology  (70)    RNA interference (RNAi) therapeutic  (2) RNA Biology, Cancer and Therapeutics  (55) RVAD  (1) SBIR, SBA, NIH, NSF  (2) Schizophrenia  (14) Scientific & Biotech Conferences: Press Coverage  (170) Scientific Publishing  (600)    Curation  (580)       Curation methodology  (37)       De novo synthesis  (15)       Dialectic  (17)       Discovery process  (69)       Evolutionary cognition  (53)       Experimental validation  (90)       Explanatory  (92)       Historical relevance  (71)       Technology Advance Assessment of  (67)       Theoretic convergence  (27)    Open Access Journals  (31) Scientist: Career considerations  (189)    Big Data & Analytics  (12)    Data Science  (9)    Women in Life Sciences  (9) Scoop.it  (17) Sensors & Analytics  (16) Sepsis  (2) Severe Autism  (3) Signaling  (94)    Phosphorylation  (40)    S-nitrosylation  (11)    Ubiquitinylation  (30) Signaling & Cell Circuits  (122) Small Molecules in Development of Therapeutic Drugs  (65) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (136) Stem Cells for Regenerative Medicine  (171)    Cardiac muscle regeneration  (17)    Competition in regenerative stem cell science  (17)    Human neural progenitor sells  (6)    Skeletal muscle regeneration  (8) STORM  (2) Stress Disorders  (18) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (156)    Inflammatory Pathophysiology  (4) Technology Transfer: Biotech and Pharmaceutical  (347) Tissue Engineering and Regenerative Medicine  (20) Tissue Microenvironment  (3) Transarterial Chemoembolization  (2) Transcriptomics  (40) Transformative Technologies in Healthcare  (9) Translational Science  (213)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (25)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (5)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (84) Trends in Global Economy  (3) Uncategorized  (1,327) Unfolded Protein Response (UPR)  (4) US and Global Economy: Trends and Findings  (6) Venture Capital  (41)    Income Geographic Distribution  (2)    Institutional Capital Raised by Female Founders  (4) virology  (1) Vision  (6) Voices of Patients and Healthcare Providers  (19) Water Transporters  (7) Wearable Tech + Digital Health  (3) Anemia  (21) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (12) Myelofibrosis  (10)

• Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.com